

21ST ANNUAL MEETING
and **EDUCATION DAY**
OF THE SOCIETY FOR NEURO-ONCOLOGY

November 17-20, 2016

Pre-conferences Begin November 16, 2016

Fairmont Scottsdale Princess

Scottsdale, Arizona

SNO

Society for NeuroOncology

PRELIMINARY PROGRAM
and **REGISTRATION INFORMATION**

MEETING OVERVIEW

The 21st Annual Meeting and Education Day of the Society for Neuro-Oncology will take place at the Fairmont Scottsdale Princess Hotel in Scottsdale, Arizona. The beautiful city of Scottsdale borders Phoenix and is only 25 minutes from the Phoenix Sky Harbor Airport. Scottsdale's slogan is "The West's Most Western Town" with its beautiful desert landscapes and southwestern cultural attractions. In addition to a lively downtown with art galleries, specialty retail, casual and upscale dining venues and night life, there are many activities for outdoor lovers as well. Visitors can participate in kayaking, horseback riding, mountain climbing or enjoy a round of golf on one of the numerous professional golf courses. There is truly something for everyone in the unique and exciting city of Scottsdale!

This year's Education Day will focus on Precision Medicine and the new WHO Classification of central nervous system tumors. The day begins with a joint session of Basic Science and Clinical & Applied Science with two keynote speakers: Malcolm Smith, MD, PhD, Associate Branch Chief for Pediatric Oncology at NIH and Margaret "Mimi" Foster Riley, JD, Professor of Law at the University of Virginia. Concurrent sessions follow with highlights including WHO classification updates, molecular diagnosis of brain tumors, clinical trials in the era of precision medicine, patient ethics involving consents and genomics, and fatigue and cognitive dysfunction. The two groups will reconvene for an exciting afternoon session featuring mock integrative diagnostic and treatment tumor boards to offer practical tips on incorporating precision medicine into neuro-oncology.

Building upon the success of past SNO meetings, this year's Scientific Meeting will feature concurrent and plenary sessions, highlighted by focused minisymposia, oral abstract presentations, rapid reports, and poster presentations. New this year will be enhanced e-talk poster presentations, "Meet the Experts" and "SNO Daily Highlights" webcasts. Special lunch tutorials and industry-sponsored symposia will provide in-depth information on a variety of timely issues impacting CNS tumor research and treatment including the 2016 revision of the WHO classification of CNS tumors and Epigenetics. Keynote presentations from Drs. David Louis, David Ellison, Joseph Costello and Bradley Bernstein will be featured highlights of the meeting. In addition, SNO is delighted to announce that Pulitzer Prize-winning author, Siddhartha Mukherjee, will deliver a special keynote address on Saturday, November 19. Dr. Mukherjee's address is made possible by the generous support of Novocure.

EDUCATIONAL OBJECTIVES

After attending this conference, participants should be able to:

- Discuss new CNS tumor immunology research concerning cell biology, tumor microenvironment, signal transduction, genomics, epigenomics, proteomics, immunology and metabolomics (*knowledge*);
- Incorporate precision medicine in neuro-oncology tailored to the individual patient's diagnosis based on genetic content, circulating biomarkers and cell analysis (*knowledge, competence, performance, patient outcomes*);
- Discuss new research on CNS immunotherapy (*knowledge*);
- Apply advances in neuro-imaging and neuropathology to diagnose, prognose, and measure response to therapy for patients with CNS tumors (*knowledge, competence, performance, patient outcomes*);
- Provide overview of WHO revisions of adult and pediatric brain tumors (*knowledge*);
- Apply therapeutic strategies and clinical trial designs related to new molecular biology research relevant to CNS tumors (*competence*);

- Utilize results of new clinical studies for central nervous system tumors for improved patient outcomes (*performance, patient outcomes*);
- Using neurocognitive intervention strategies, create a plan to diminish the impact of brain tumors and their treatments on patients and quality of life (*knowledge, competence, performance, patient outcomes*);
- Describe new initiatives in palliative neuro-oncology and utilize symptom management initiatives to improve quality of life for brain tumor patients (*knowledge, performance, patient outcomes*).

TARGET AUDIENCE

This conference should be of value to neuro-oncologists, medical oncologists, adult and pediatric neurosurgeons, pediatric neuro-oncologists, neuroradiologists, neuropathologists, radiation oncologists, neuro-psychologists, epidemiologists, basic and translational scientists and nurses.

EDUCATIONAL METHODS

Lectures, Question-and-Answer Sessions, Panel Discussions, Posters, etc.

EVALUATION

A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

ACCREDITATION/CREDIT DESIGNATION

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Texas MD Anderson Cancer Center and the Society for Neuro-Oncology. The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of **26.50 AMA PRA Category 1 Credits™**. Physicians should claim only credit commensurate with the extent of their participation in the activity.

The presentations included in the Applied Neuro-Oncology (Quality of Life) Interventions section have been designated by The University of Texas MD Anderson Cancer Center for **3.75 AMA PRA Category 1 Credits™** in medical ethics and/or professional responsibility.

THE UNIVERSITY OF TEXAS
MD Anderson
Cancer Center
Making Cancer History™



CME CERTIFICATES AND ATTENDANCE VERIFICATION CERTIFICATES

Certificates awarding *AMA PRA Category 1 Credits™* or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form. Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially influence the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity. Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

GALA DINNER

This year's gala dinner, the social highlight of the meeting, will feature a "Cirque du Soleil" style theme and will be held at the exclusive Scottsdale Airpark on Saturday evening, November 19th. The newly remodeled indoor-outdoor venue provides an elegant dining setting, as well as an expansive patio with unparalleled views of the action at this elite airpark. A magnificent collection of private aircraft will be on display for our event as well as live entertainment and dancing.

Deluxe motor coaches will transfer you on a short 15-minute ride from the host hotel to an amazing and memorable night full of fun. A gala dinner ticket can be added to your registration at any time. Tickets are limited and were sold out at last year's meeting. We strongly suggest you purchase your tickets early as they are first-come, first serve. We hope you will join us for this very special evening!

REGISTRATION INFORMATION

Register Online: www.soc-neuro-onc.org. Online registration is the preferred method of registering for the meeting. Registrants can pay with a major credit card, or can choose to be invoiced via the online system and pay by check or money-order. If you require a paper registration form, or have questions about registration, please contact Linda Greer, Tel. (346) 980-6935. Email: linda@soc-neuro-onc.org.

We prefer payment prior to arrival in Scottsdale. Please note that a surcharge will be assessed for all on-site registrations and/or registration payments.

ACCOMMODATIONS

The Fairmont Scottsdale Princess is the conference venue for this year's meeting. This beautiful property is centered in the blooming Sonoran Desert and close to some of Scottsdale's most exciting indoor/outdoor dining and entertainment venues. The discounted room rate at the Fairmont is only \$229.00 per night. Additional hotel options are listed on the SNO website, and a shuttle bus will be provided to and from the Fairmont.

Special Assistance: Contact SNO at (346) 980-6935 if you have any special dietary or ADA accommodation needs.

REFUNDS /CANCELLATIONS

The pre-registration deadline for the lowest registration rates is October 10, 2016, 11:59pm, CST. The online registration deadline is November 9. For registrations after this date, attendees must register on-site and on-site surcharges will apply.

NEW THIS YEAR!

The SNO meeting will provide some exciting new features this year including:

- **NEW AND ENHANCED "E-TALK" PRESENTATIONS**
- **INTERACTIVE E-POSTER TOUCH-SCREENS**
- **"MEET THE EXPERT" VIDEOS - CONTINUOUSLY PLAYED THROUGHOUT THE MEETING**
- **"SNO DAILY HIGHLIGHTS" WEBCASTS**
- **IMPROVED PRESENTATION MANAGEMENT SYSTEM WITH REMOTE UPLOAD OPTION**
- **SPEAKER Q&A VIA TEXT AND IN-PERSON DURING PLENARY SESSIONS**
- **ENHANCED ON-SITE APP**

REGISTER FOR SPECIAL PRE-CONFERENCE SESSIONS STARTING NOVEMBER 16!

Attendees have the option of registering for the following special pre-conference sessions:

NEURO-ONCOLOGY REVIEW COURSE

Chair: Maciej Mrugala

SNO is pleased to announce a full-day Neuro-Oncology Review Course as part of its educational programs for 2016. The course will take place on Wednesday, November 16.

CNS ANTICANCER DRUG DISCOVERY AND DEVELOPMENT CONFERENCE

Chair: Victor Levin

Following the first meeting in 2014, this year, SNO is pleased to host the second CNS Anticancer Drug Discovery and Development Conference, which will be held Wednesday/Thursday, November 16-17, immediately prior to the SNO Annual Meeting.

PROGRAM DETAILS ARE INCLUDED FURTHER IN THIS BROCHURE. TO REGISTER FOR EITHER OF THESE PRE-CONFERENCE SESSIONS, VISIT THE SNO WEBSITE
www.soc-neuro-onc.org

SCIENTIFIC COMMITTEE

Education Day Chairs

Manmeet Ahluwalia
Jaishri Blakeley
Kristina Hardy
Keith Ligon

Scientific Meeting Chairs

Manish Aghi
Tracy Batchelor

Cancellations must be received in writing no later than November 9; registration fees will be refunded less a \$50 handling fee. Cancellations received after November 9 cannot be refunded, but the meeting registration can be transferred to another person with written authorization. E-mail all cancellation and transfer requests to Program Registrar Linda Greer, linda@soc-neuro-onc.org.

PRE-CONFERENCE SESSIONS

Wednesday, November 16, 2016 | Neuro-Oncology Review Course

Building on the success of the 2015 program, this year the organizers will host a full-day of fast paced, high quality education and CME credits for all participants. The faculty of the course, selected from top neuro-oncology programs, will offer a comprehensive overview of clinical neuro-oncology. In addition to the course syllabus, participants will receive a set of multiple-choice questions that allow for consolidation of the acquired material and help them prepare for the specialty boards.

Chair: *Maciej Mrugala*

6:15-7:15am LIGHT CONTINENTAL BREAKFAST

7:15-7:30am Welcome and Introduction
Maciej Mrugala (Chair)

7:30-8:15am Primary brain tumors – pathology, grading and prognosis – new WHO classification
Peter Canoll

8:15-9:00am Neurosurgical management of brain tumors
Michael Lim

9:00-9:45am Medical complications in neuro-oncology patients
Katherine Peters

9:45-10:00am BREAK

10:00-10:45am Management of primary CNS tumors - PART I – gliomas
Erin Dunbar

10:45-11:30am Principles of radiotherapy in neuro-oncology and its side effects
Helen Shih

11:30-12:15pm Management of primary brain tumors - PART II – non-glial tumors
Rimas Lucas

12:15-1:15pm LUNCH

1:15-2:00pm Metastatic disease in the nervous system
Maciej Mrugala

2:00-2:45pm Chemotherapy in neuro-oncology: principles and practice
David Peereboom

2:45-3:30pm Neuro-radiology pearls for the neuro-oncologist
James Fink

3:30-3:45pm BREAK

3:45-4:30pm Pediatric neuro-oncology highlights
Sonia Partap

4:30-5:15pm Palliative care for a neuro-oncologist
Lynne Taylor

5:15-6:00pm Non-metastatic neurologic complications of cancer
Lisa Rogers

6:00pm ADJOURN

PRE-CONFERENCE SESSIONS

Wednesday, November 16, 2016 | CNS Anticancer Drug Discovery and Development

This conference, organized by academic and pharmaceutical industry scientists and physicians, is intended to improve drug discovery and development for primary infiltrative tumors in adults and children as well as tumors that metastasize to the CNS. It will provide education and networking opportunities for scientists in academia, government, and the pharmaceutical industry that will, we hope, foster greater collaboration and, thereby, improve patient outcomes.

Chair: Victor Levin

8:00-8:30am LIGHT CONTINENTAL BREAKFAST

8:30-8:35am Welcome and Introduction
Victor Levin

Session 1: Clinical Reality and Pharmaceutical Challenges

8:35-8:55am Challenges for the treatment of infiltrative and secondary CNS tumors and overview of conference
Victor Levin

8:55-9:15am Prediction of BBB transport and CNS drug distribution; considerations for anticancer drugs
Elisabeth de Lange

9:15-9:35am Integrating drug-target kinetics into predictions of in vivo drug activity
Peter Tonge

9:35-9:55am Small molecule kinase inhibitors for brain cancer: limitations, challenges and opportunities
Timothy Heffron

9:55-10:35am Session 1 Discussion
Moderator: Lauren Abrey

10:35-10:55am BREAK

Session 2: Economic and Regulatory Challenges

10:55-11:15am Leaving breakthrough drugs on the laboratory shelf: How the patent system distorts industry drug development, and how to fix it
Benjamin Roin

11:15-11:25am Regulatory perspectives on developing products for rare tumors
Joohee Sul

11:25-11:35am Industry challenges to develop therapies for CNS cancers
Lauren Abrey

11:35-12:15pm Session 2 Discussion
Moderator: Victor Levin

12:15-1:15pm LUNCH

Session 3: Drug Targets and Brain Penetrant Drugs

1:15-1:30pm A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma
William Weiss

1:30-1:45pm The discovery and early clinical development of AZD3759, a fully BBB-penetrant EGFR kinase inhibitor
Xiaolin Zhang

1:45-2:00pm Clinical development of IDH inhibitors in glioma
Chris Bowden

PRE-CONFERENCE SESSIONS

Wednesday, November 16, 2016 | CNS Anticancer Drug Discovery and Development

2:00-2:12pm ABST 20	Novel oral prodrugs of 6-diazo-5-oxo norleucine improve brain penetration and demonstrate efficacy against orthotopic brain tumor xenografts <i>Allison Hanaford</i>
2:12-2:24pm ABST 8	A novel BBB-permeable chemotherapeutic agent for the treatment of glioblastoma <i>Theodore Nicolaides</i>
2:24-2:50pm	Session 3 Discussion <i>Moderator: Timothy Heffron</i>

2:50-3:10pm BREAK

Session 4: Imaging of Drugs and Drug Effects in the CNS

3:10-3:30pm	Emerging strategies in the molecular imaging of brain tumors <i>Sanjiv Sam Gambhir</i>
3:30-3:50pm	MRI and using humans as the experimental model in drug development <i>Elizabeth Gerstner</i>
3:50-4:10pm	Visualizing human neurochemical (dys)function using positron emission tomography <i>Frederick A. Schroeder</i>
4:10-4:30pm	Hyperpolarized ¹³ C magnetic resonance spectroscopic imaging of brain tumors and their response to therapy <i>Sabrina Ronen</i>
4:30-4:42pm ABST 27	Modeling of drug delivery in brain tumors and validation with in-vivo imaging <i>Jayashree Kalpathy-Cramer</i>
4:42-5:15pm	Session 4 Discussion <i>Moderator: Peter Tonge</i>

5:15-7:15pm RECEPTION

PRE-CONFERENCE SESSIONS

Thursday, November 17, 2016 | CNS Anticancer Drug Discovery and Development

7:45-8:15am LIGHT CONTINENTAL BREAKFAST

Session 5: New Types of Drugs and Drug Delivery Opportunities

- 8:15-8:35am Modular nanomedicine for brain and spinal cord-targeted chemotherapy
Rachael Sirianni
- 8:35-8:55am Increasing drug-target residence time by covalent interactions
Jack Taunton
- 8:55-9:07am NEO 214, Rolipram conjugated to perillyl alcohol is a novel drug that crosses the blood-brain barrier and reduces
ABST 12 brain tumor progression in vivo
Florence Hofman
- 9:07-9:19am Successful cancer-selective gene delivery following intravenous Toca 511 delivery in patients with recurrent high
ABST 4 grade glioma (HGG)
Timothy Cloughesy
- 9:19-9:31am Using Monoamine Oxidase B's catalytic activity to activate prodrugs
ABST 9
Martyn Sharpe
- 9:31-9:43am Laser interstitial thermal therapy of glioblastoma induces temporary disruption of the peritumoral blood brain
ABST 26 barrier (BBB) and may improve efficacy of chemotherapy with poor CNS penetration
David Tran
- 9:43-9:55am Precision functional genomics for glioblastoma: identifying molecular therapeutic targets using CRISPR-Cas9 and
ABST 22 RNAi technologies in patient isolates
Pia Hoellerbauer
- 9:55-10:07am Combining ibudilast with temozolomide for recurrent glioblastoma
ABST 17
Kerrie McDonald
- 10:07-10:40am Session 5 Discussion
Moderator: Arvin Dar

10:40-11:00am BREAK

Session 6: Modeling Drug Effects and Tumor Growth

- 11:00-11:20am Patient-specific mathematical neuro-oncology: Identifying and predicting response
Kristen Swanson
- 11:20-11:40am Towards integrated mechanistic models of glioblastoma signaling for precision pharmacology
Marc Birtwistle
- 11:40-11:55am Mice: The worst pre-clinical models...except for all the others
Robert Wechsler-Reya
- 11:55-12:15pm Phase I trials: Bridging the divide between preclinical results and the clinic
Alexander Anderson
- 12:15-12:27pm Combining Toca 511 and 5-fluorocytosine with checkpoint inhibitors significantly reduced tumor burden in a mouse
ABST 3 model of glioma
Leah Mitchell
- 12:27-1:00pm Session 6 Discussion
Moderator: Jim Gallo

1:00-2:00pm LUNCH

PRE-CONFERENCE SESSIONS

Thursday, November 17, 2016 | CNS Anticancer Drug Discovery and Development

Session 7: Drug Targets and the CNS Tumor Micro-environment

2:00-2:20pm	Modulation of glioblastoma tumorigenicity by tumor microenvironment <i>Clark Chen</i>
2:20-2:40pm	Brain microenvironment-induced PTEN loss primes tumor outgrowth that can be suppressed by targeting CCL2 <i>Dihua Yu</i>
2:40-2:52pm ABST 14	OMX, a broad-acting modulator of the hypoxic tumor microenvironment, acts as a radiosensitizer and promotes anti-cancer T cell activity in orthotopic glioblastoma <i>Ana Krtolica</i>
2:52-3:04pm ABST 24	Molecular mechanisms of dianhydrogalactitol (VAL-083) in overcoming GBM chemoresistance <i>Jeffrey Bacha</i>
3:04-3:16pm ABST 16	Developing dual-acting small molecules for glioma therapy <i>Frank Sorgi</i>
3:16-3:28pm ABST 21	Natural killer cell mediated immunotherapeutic strategy for malignant meningioma <i>Shuyu Hao</i>
3:28-4:00pm	Session 7 Discussion <i>Moderator: William Weiss</i>
4:00-4:05pm	Closing Remarks
4:05pm	ADJOURN

EDUCATION DAY PROGRAM

Thursday, November 17, 2016 | SNO Education Day

Co-chairs: Manmeet Ahluwalia, Jaishri Blakeley, Kristina Hardy, Keith Ligon

7:00-8:00am LIGHT CONTINENTAL BREAKFAST

MORNING JOINT SESSION

Precision Medicine and WHO Classification

- 8:00-8:10am Welcome and Introduction
Manmeet Ahluwalia, Jaishri Blakeley, Kristina Hardy, Keith Ligon (Education Day Co-chairs)
- 8:10-8:55am **Keynote Presentation:** From precision medicine to medicine
Malcolm Smith
- 8:55-9:40am **Keynote Presentation:** Regulation of neuro-oncology research and clinical care in the era of big data
Margaret "Mimi" Foster Riley

9:40-10:00am BREAK

CONCURRENT BREAKOUT SESSION

Basic Science and Clinical Science

- 10:00-10:30am WHO overview
Arie Perry
- 10:30-11:00am Advances in the molecular genetics of meningioma
Sandro Santagata
- 11:00-11:30am IDH-omas
Daniel Brat
- 11:30-12:00pm Pediatric gliomas
Cynthia Hawkins

CONCURRENT BREAKOUT SESSION

Clinical and Applied Neuro-Oncology

Keeping the patient in focus: from big data to improving daily life

- 10:00-10:30am Informed consent in the era of big data
Pilar Ossorio
- 10:30-11:00am Patient scientist: perspective on access to data
Steven Keating
- 11:00-11:30am Clinical and research implications associated with the transition to electronic health records
Jennifer Cahill
- 11:30-12:00pm The use of evidence-based neuropsychological assessment approaches in cancer: a prevention-based model of neuropsychological service delivery
Karin Walsh

12:00-1:00pm LUNCH

- | | | | |
|-------------|---|-------------|--|
| 1:00-1:20pm | Immuno-oncology diagnostics in cancer
<i>David Rimm</i> | 1:00-1:25pm | Pro-inflammatory cytokines and their association with fatigue and cognitive symptoms in cancer
<i>Arash Asher</i> |
| 1:20-1:40pm | Surgical interventions in the era of precision medicine
<i>Fredrick Lang</i> | 1:25-1:50pm | Interventions for fatigue and cognitive dysfunction in people with gliomas
<i>David Cachia</i> |
| 1:40-2:00pm | Radiation in the era of precision medicine
<i>Prakash Chinnaiyan</i> | 1:50-2:15pm | Translation of pre-clinical models to clinical interventions for radiation associated cognitive injury
<i>Jorge Dietrich</i> |
| 2:00-2:20pm | Clinical trials in the era of precision medicine
<i>Brian Alexander</i> | 2:15-2:40pm | Neuro-oncology burn-out and career satisfaction: overview and preliminary results
<i>Barbara O'Brien, Shlomit Yust-Katz, Alvina Acquaye</i> |
| 2:20-2:40pm | Liquid biopsy in precision medicine
<i>Chetan Bettegowda</i> | | |

2:40-3:00pm BREAK

EDUCATION DAY PROGRAM

Thursday, November 17, 2016 | SNO Education Day

AFTERNOON JOINT SESSION

- 3:00-4:00pm Mock integrative diagnostic tumor board
Keith Ligon, Charles Eberhart, Joanna Phillips, Nikolaus Schultz, Robert Jenkins
- 4:00-5:00pm Mock molecular treatment tumor board
Manmeet Ahluwalia, Jan Buckner, Martin van den Bent, Lola Chambless, Terri Armstrong, Minesh Mehta

5:00pm ADJOURN

- 5:30-7:30pm **Industry Supported Symposia**
Not sponsored by The University of Texas MD Anderson Cancer Center
- New considerations for the treatment of glioblastoma multiforme (GBM): evaluating the potential for immune checkpoint inhibitors

7:30-10:00pm **WELCOME RECEPTION**

7:30-8:30pm Young Investigator's Career Development and Networking Session
(Pre-registration required. See SNO website for further details.)

ABSTRACT CODES

ACTR	Adult Clinical Trials - Non-Immunological	MPTH	Molecular Pathology and Classification (Adult and Pediatric)
ANGI	Angiogenesis and Invasion	NCOG	Neuro-Cognitive Outcomes
ATIM	Adult Clinical Trials - Immunological	NIMG	Neuro-Imaging
BMET	Brain Metastases	NTOX	Neurotoxicity of Therapy
CBIO	Cell Biology	PALL	Supportive Palliative Care
CSIG	Cell Signaling and Signaling Pathways	PDCT	Clinical Trials and Outcomes - Pediatrics
DDIS	Drug Discovery	PDTB	Pediatric Tumors - Preclinical Studies (Non-Immunological)
DRES	Drug Resistance	QLIF	Quality of Life
EPID	Epidemiology	RARE	Rare Tumors
EXTH	Experimental Therapeutics - Preclinical Studies (Non-Immunological)	RBIO	Radiobiology
GENT	Genetics and Epigenetics	RTHP	Radiation Therapy
IMST	Immunology - Preclinical Studies	STMC	Stem Cells
METB	Metabolomics	SURG	Surgical Therapy
MNGO	Meningioma	TMIC	Tumor Microenvironment
		TMOD	Tumor Models

MAIN MEETING PROGRAM

Friday, November 18, 2016

7:00-9:00am LIGHT CONTINENTAL BREAKFAST

7:00-8:30am **SUNRISE SESSIONS**

Novel Metabolic Targets in Glioma

Daniel Cahill, Howard Fine (Co-chairs)

- Progress on metabolic targeting therapy for IDH mutant and wild-type malignant glioma
Gregory Riggins
- The cancer metabolism and beyond
Zhimin Lu
- Alterations of metabolism in IDH mutant glioma
Daniel Cahill
- Insights into the metabolic reprogramming of gliomas from ¹³C-NMR studies in patients
Robert Bachoo

Tumor Predisposition and Genetic Counseling in a Neuro-Oncology Practice

Erin Dunbar, Krista Qualmann (Co-chairs)

- Tumor predisposition syndromes and practical resources
Michelle Jackson
- Risk assessment and genetic counseling: putting the pieces together
Krista Qualmann
- Screening guidelines for tumor syndromes
Erin Dunbar
- Clinical management recommendations
John Henson

EAANO/SNO: Umbrella and Basket Trials in Neuro-Oncology

Tracy Batchelor, Michael Weller (Co-chairs)

- Molecular screening platforms in the US
Kenneth Aldape
- Molecular screening platforms in Europe
Monika Hegi
- AGILE
Timothy Cloughesy
- N2M2
Wolfgang Wick
- Targeted therapy for meningioma in the US
Priscilla Brastianos
- Targeted therapy for meningioma in Europe
Emilie Le Rhun

Quality of Life - Net Clinical Benefit of Brain Tumor Treatment

Terri Armstrong (Chair)

- Moving beyond toxicity reporting to prediction and reduction in CNS tumor patients
Terri Armstrong
- Radiation toxicity: understanding pathophysiology and methods to reduce toxicity in adults
Jing Li, Paul Brown
- Clinical and genomic predictors of toxicity
Michael Scheurer
- Long term functional toxicity in adult survivors of pediatric CNS tumors: lessons from the St. Jude lifetime cohort study
Tara Brinkman

ASNO/Radiation Oncology

Ryo Nishikawa, Erik Sulman (Co-chairs)

- Clinical outcomes and advances in the use of proton therapy for brain tumors
David Grosshans
- Particle therapy in the management of intracranial and base of skull tumors
Jiade Lu
- Modern radiation oncology for brain tumors: What is the role of high LET-beams?
Stephanie Combs
- Boron, neutron capture therapy for malignant brain tumors, from reactor to accelerator
Shin-Ichi Miyatake

Immuno-Epidemiology of Glioma

Kyle Walsh (Chair)

- Association between prediagnostic cytokines and glioma
Judith Schwartzbaum
- Investigating the role of viruses and immune cells in glioma etiology
Joseph Wiemels
- Epidemiology informs glioma immunotherapy
Peter Fecci

MAIN MEETING PROGRAM

Friday, November 18, 2016

Co-chairs: Manish Aghi, Tracy Batchelor

8:30-12:00pm SNO PLENARY SESSION

8:30-8:35am Welcome and Introduction of Scientific Program
Manish Aghi, Tracy Batchelor

8:35-9:30am **Keynote Presentation:** The 2016 WHO classification of CNS tumors: an overview and a review of diffuse gliomas in adults
David Louis

9:30-10:00am **Keynote Presentation:** The 2016 WHO classification of CNS tumors - What's new for pediatrics?
David Ellison

10:00-10:15am BREAK

10:15-10:45am WHO Panel Discussion
E. Antonio Chiocca (Moderator), Arie Perry, David Arons, Carol Kruchko, Amar Gajjar, Michael Weller
Supported by the SNO Public Policy Committee

10:45-11:15am **Abhijit Guha Award Introduction:** *E. Antonio Chiocca*

Abhijit Guha Award Recipient: *Michael Taylor*

Top Scoring Abstracts

Moderators: Manish Aghi, Tracy Batchelor

11:15-11:30am Late Breaking Abstract

11:30-11:45am ACT IV: An international, double-blind, phase 3 trial of rindopepimut in newly diagnosed, EGFRvIII-expressing glioblastoma
ATIM-03
Weller M, Butowski N, Tran D, Recht L, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust S, Iwamoto F, Drappatz J, O'Rourke D, Wong M, Finocchiaro G, Perry J, Wick W, He Y, Davis T, Stupp R, Sampson J

11:45-12:00pm Single-cell profiling of glioblastoma biopsies identifies a family of activating PDGF-receptor deletions
GENT-22
Mueller S, Liu S, Malatesta M, Aghi M, Kriegstein A, Kohanbash G, Lim D, Diaz A
ADULT BASIC RESEARCH AWARD

12:15-1:15pm LUNCH

LUNCHTIME TUTORIALS AND EDUCATIONAL SESSIONS

Not sponsored by The University of Texas MD Anderson Cancer Center

Health Outcomes Measures

Isabel Arrillaga-Romany, Natalie Riblet (Co-chairs)

- Increasing efficiency of molecular brain tumor testing, *Justin Jordan*
- Integrated care of patients diagnosed with brain metastases, *Camilo Fadul*
- Successes and challenges in implementing a clinical care pathway to improve the acute care of patients with glioma, *Natalie Riblet*
- Updates on the performance of a hospital-wide management pathway for newly diagnosed single brain mass, *Isabel Arrillaga-Romany*

Laser-induced Thermal Therapy for Brain Tumors

Gene Barnett (Chair)

- The NeuroBlate System and treatment of high-grade gliomas, *Gene Barnett*
- The Visualase System for treatment of high-grade glioma, *Shabbar Danish*
- Laser ablation after radiosurgery for brain metastases, *Veronica Chiang*
- Evolution of radiographic changes after laser ablation of brain tumors, *Pallavi Tiwari*

MAIN MEETING PROGRAM

Friday, November 18, 2016

12:15-1:15pm LUNCH, continued

2016 WHO Revision-Practical Implications

Guido Reifenberger, Wolfgang Wick (Co-chairs)

- Revised WHO classification of gliomas in adults - implications for daily diagnostics, *Guido Reifenberger*
- Revised WHO classification of gliomas in adults – what does it mean for the clinician? *Wolfgang Wick*
- Revised WHO classification of childhood tumors – clinicopathological implications, *David Ellison*

Clinical Trials for Junior Investigators

Evanthia Galanis, Patrick Wen (Co-chairs)

- From preclinical data to phase I testing, *Patrick Wen*
- Phase II/III trial designs in neurooncology, *Evanthia Galanis*
- Correlative analysis/biomarker driven trial designs, *Brian Alexander*

Genomics

Scott Carter, Roel Verhaak (Co-chairs)

- Dissection tumor evolution in glioblastoma, *Roel Verhaak*
- Genomic evolution of brain metastasis, *Scott Carter*
- Novel brain tumor subtypes identified by genome-wide methylome profiling, *David Jones*

Industry Supported Symposia

Not sponsored by The University of Texas MD Anderson Cancer Center

- The changing landscape of management of brain metastases
- Clinical perspectives on Optune: a case-based approach
- Impact of pre-surgical transcranial magnetic stimulation on glioma management

1:30-5:00pm CONCURRENT SESSIONS

CONCURRENT SESSION 2A

Clinical Trials I

Moderators: Brian O'Neill, Wolfgang Wick

- 1:30-1:45pm Invited Speaker: Challenges in brain tumor clinical research in the era of big data
Mark Gilbert
- 1:45-2:00pm Results of the phase Ib KEYNOTE-028 multi-cohort trial of pembrolizumab monotherapy in patients with recurrent PD-L1-positive glioblastoma multiforme (GBM)
ATIM-35
ADULT CLINICAL RESEARCH AWARD
Reardon DA, Kim T-M, Frenel J-S, Santoro A, Lopez J, Subramaniam D, Siu L, Rodon J, Tamura K, Saraf S, Morosky A, Stein K, Soria J-C
- 2:00-2:10pm Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab [DUR]) in patients with glioblastoma (GBM): results for cohort B (DUR monotherapy), bevacizumab (BEV) naïve patients with recurrent GBM
ATIM-04
Reardon DA, Kaley T, Dietrich J, Lim M, Dunn G, Gan H, Cloughesy T, Clarke J, Park A, Macri M, Ryan A, Ricciardi T, Reddy V, Venhaus R

2:10-2:20pm
ATIM-21

IMA950 peptide-based vaccine adjuvanted with Poly-ICLC in combination with standard therapy in newly diagnosed HLA-A2 glioblastoma patients: preliminary results
Migliorini D, Dutoit V, Walker P, Dietrich P-Y

2:20-2:30pm
ACTR-07

Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified (EGFRamp), recurrent glioblastoma (rGBM)
van den Bent M, Gan H, Lassman A, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors L, Papadopoulos K, Penas-Prado M, Simes J, Walbert T, Scott A, Gomez E, Lee H-J, Roberts-Rapp L, Xiong H, Bain E, Holen K, Maag D, Reardon DA

2:30-2:40pm
ACTR-46

AG120, a first-in-class mutant IDH1 inhibitor in patients with recurrent or progressive IDH1 mutant glioma: results from the phase 1 glioma expansion cohorts
Mellinghoff IK, Touat M, Maher E, DeLaFuente M, Cloughesy TF, Holdhoff M, Cote G, Burris H, Janku F, Huang R, Young R, Ellingson B, Auer J, Liu H, Hurov J, Yen K, Agresta S, Attar E, Pandya S, Wen PY

MAIN MEETING PROGRAM

Friday, November 18, 2016

2:40-2:50pm
ACTR-09
Clinical results of the EORTC randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence of grade II or III glioma without 1p/19q co-deletion
van den Bent M, Clement P, Vos F, Platten M, Mulholland P, Taphoorn M, Lewis J, Gorlia T, Golfopoulos V, Idbaih A, Chinot O

2:50-3:00pm Discussion

CONCURRENT SESSION 2B

Experimental Therapeutics/Models/Drug Discovery/ Drug Resistance (Tumor Biology I)

Moderators: Howard Colman, Antonio Iavarone

1:30-1:40pm
EXTH-34
YOUNG INVESTIGATOR AWARD
CLINICAL RESEARCH
Epigenomic treatment for IDH wild-type grade III glioma, targeting dysregulation of EZH2-H3K27me3
Ohka F, Deguchi S, Suzuki H, Aoki K, Katsushima K, Shinjo K, Wakabayashi T, Kondo Y, Natsume A

1:40-1:50pm
TMOD-25
PEDIATRIC TRANSLATIONAL RESEARCH AWARD
Modeling adult proneural and mesenchymal glioblastoma using RCAS/t-va technology
Herting C, Hambarzumyan D

RAPID REPORTS

1:50-1:55pm
TMOD-02
Developing models of therapy resistance for the identification of treatment-refractory cell population(s) in human glioblastoma
Qazi M, Vora P, Venugopal C, Bakhshinyan D, Nixon A, Brown K, Subapanditha M, Chokshi C, Murty N, Moffat J, Singh S

1:55-2:00pm
TMOD-03
Cell-of-origin for GBM and its application for translational research
Kim J, Gonzalez P, Zhang G, Zong H

2:00-2:05pm
EXTH-29
Development of TERT-targeting therapy against glioblastoma
Takahashi M, Matsushita Y, Miki S, Fukuoka K, Maida Y, Yasukawa M, Hayashi M, Mukasa A, Nishikawa R, Tamura K, Hamada A, Masutomi K, Narita Y, Ichimura K

2:05-2:10pm
EXTH-59
mtTERT promoter as a target for treatment of glioblastoma
Dhruv H, Kang H-J, Peng S, Gokhale V, Hurley L, Berens M

2:10-2:15pm
DRES-09
Mechanisms of resistance to EGFR inhibition reveal metabolic vulnerabilities in human GBM
McKinney A, Lindberg O, Lu K, Simonds E, Nicolaides T, Yong W, Lai A, Hegi M, Weiss W, Phillips J

2:15-2:20pm
DRES-11
A cross-activating c-Met/ β 1 integrin complex drives therapeutic resistance in glioblastoma
Jahangiri A, Sidorov M, Won Han S, Chen W, Rick J, Schneidman-Duhovny D, Mascharak S, De Lay M, Wagner J, Castro B, Imber B, Flanigan P, Kuang R, Lu K, Bergers G, Sali A, Weiss W, Aghi M

2:20-2:25pm
EXTH-33
OS2966 dramatically enhances preclinical efficacy of oncolytic virus therapy
Carbonell S, Young Yoo J, Nallanagulagari T, Jaime-Ramirez AC, Bolyard C, Jin Lee T, Zhang J, Croce C, Wu E, Aghi M, Kaur B,

2:25-2:30pm
DRES-10
The adverse impact of temozolomide therapy at initial diagnosis of grade II glioma on overall survival
Zhang B, Decker P, Kizilbash S

2:30-2:35pm
DRES-13
Extended temozolomide for newly diagnosed glioblastoma: an analysis of the German Glioma Network
Gramatzki D, Kickingereder P, Hentschel B, Herrlinger U, Schackert G, Tonn J-C, d Westphal M, Sabel M, Schlegel U, Wick W, Reifenberger G, Löffler M, Bendszus M, Weller M

2:35-2:40pm
DDIS-12
A facile, robust and predictive in vitro blood-brain-barrier model for high-throughput screening and discovery of brain-penetrating agents
Cho C-F, Wolfe J, Fazden C, Hornburg K, Chiocca EA, Pentelute B, Lawler SE

2:40-2:45pm
TMOD-23
Development and application of a novel model of human lung-to-brain metastasis to identify genetic regulators of brain metastasis initiating cells
Singh M, Venugopal C, Tokar T, Brown K, McFarlane N, Bakhshinyan D, Vora P, Qazi M, Mahendram S, Vijaykumar T, Manoranjan B, Tong A, Durrer K, Murty N, Hallet R, Hassell J, Kaplan D, Cutz J, Jurisica J, Moffat S, Singh S

2:45-3:00pm Discussion

CONCURRENT SESSION 2C

Surgery

Moderators: Constantinos Hadjipanayis, Brian Nahed

1:30-1:45pm
SURG-13
ANDREW PARSA
YOUNG INVESTIGATOR
BASIC/TRANSLATIONAL
RESEARCH AWARD
Stimulated Raman scattering microscopy provides diagnostic intraoperative histopathologic images in brain tumor patients
Orringer DA, Pandian B, Hollon, TC, Niknafs YS, Boyle J, Lewis S, Hervey-Jumper SL, Garton H, Maher CO, Heth JA, Sagher O, Snuderl M, Venneti S, Ramkissoon S, McFadden KA, Fisher-Hubbard A, Lieberman A, Johnson TD, Xie XS, Freudiger CW, Camelo-Piragua S

MAIN MEETING PROGRAM

Friday, November 18, 2016

RAPID REPORTS

1:45-1:50pm
SURG-31 Intraoperative molecular diagnosis and surgical guidance using iKnife real-time mass spectrometry
Vagas B, White E, Hui-Yu H, Balog J, Galea D, Takats Z, O'Neill K

1:50-1:55pm
SURG-38 Direct evidence of plasticity within primary motor and sensory cortices via direct electrical stimulation in glioblastoma patients undergoing repeat awake craniotomy
Gibb W, Kong N, Tate M

1:55-2:00pm
SURG-15 Integrating molecular markers and extent of resection for risk stratification of patients with newly-diagnosed glioblastoma: A multicentre study
Sayeed W, Batuyong E, Li H, Cadieux M, Kelly J, Scott J, Semenchuk J, Pitz M, Easaw J

2:00-2:05pm
SURG-30 Using the neurologic assessment in neuro-oncology (NANO) scale as a predictive assessment tool for survival in patients with primary glioblastoma
Ung T, Ney D, Damek D, Yousseff S, Lillehei K, Ormond D

2:05-2:10pm
SURG-21 Case-matched study of effect of intra-operative MRI on extent of resection and clinical outcome in glioma patients undergoing surgical resection
Everson R, Tucker A, Garrett M, Marcus L, Harris R, Prins R, Ellingson B, Liau L

2:10-2:15pm
SURG-28 Combination of intraoperative MRI with electrophysiological monitoring for enhanced brain tumor resection
Planchard R, Brown D, Shepherd D, Parney IF

2:15-2:20pm
SURG-20 First in-human study of a novel device for convection enhanced delivery of topotecan and gadolinium for recurrent GBM: Interim results
Vogelbaum M, Ahluwalia M, Peereboom D, Stevens G, Mohammadi A, Brewer C

2:20-2:25pm
SURG-37 Modern postoperative seizure prophylaxis with levetiracetam in over 300 newly diagnosed glioblastoma patients
Jahangiri A, Flanigan PM, Choi S, Chou A, Arnush M, Bruhn J, Kuang R, Truong A, Clarke J, Chang E, McDermott M, Chang S, Berger MS, Aghi M

2:25-2:30pm
BMET-28 The novel brain penetrating peptide-drug conjugate ANG1005 shows activity in LC subset of patients with recurrent CNS metastasis from breast cancer
Kumthekar P, Tang S-C, Brenner A, Kesari S, Piccioni D, Anders C, Carrillo J, Chalasani P, Kabos P, Ahluwalia MS, Ibrahim N

2:30-2:35pm
BMET-02 Metastases affecting the motor eloquent cortex should be resected with preoperative motor mapping data by Ntms
Krieg SM, Ille S, Picht T, Sollmann N, Bährend I, Ringel F, Nagarajan S, Vajkoczy P, Berger MS, Meyer B, Tarapore PE

2:35-2:40pm
SURG-27 Stereotactic laser ablation (SLA) as treatment for brain metastases that recur after stereotactic radiosurgery: a multi-institutional experience
Chen C, Amaan M, Rennert R, Carroll K, Sharma M, Barnholtz-Sloan J, Myers C, Barnett G, Smith K, Mohammadi A, Sloan A

2:40-2:45pm
RTHP-06 Treatment of vestibular schwannoma with stereotactic radiation: a single institution comparison of 3 different linac-based fractionation schemas
Goyal U, Slane B, Grow J, Morrison C, Hullet C, Georgiev G, Sanan A, Stea B

2:45-2:50pm
SURG-10 Impact of insurance status and race on receipt of surgery for acoustic neuroma: a National Cancer Database analysis
McClelland III S, Kim E, Murphy JD, Thomas Jr CR, Jaboin JJ

2:50-3:00pm Discussion

3:00-3:15pm BREAK

CONCURRENT SESSION 3A

Clinical Trials II

Moderators: Michael Lim, Warren Mason

RAPID REPORTS

3:15-3:20pm
ACTR-29 Final results from the AXIG trial: A randomized phase II clinical trial investigating Axitinib alone or in combination with CCNU in patients with recurrent glioblastoma
Duerinck J, Du Four S, Bouttens F, Verschaeye V, Chaskis C, Andre C, Van Fraeyenhove F, D'haene N, Salmon I, Neyns B

3:20-3:25pm
ATIM-18 Phase I dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG)
Desjardins A, Randazzo D, Chandramohan V, Sampson J, Peters K, Vlahovic G, Threatt S, Herndon J, Boulton S, Lally-Goss D, Healy P, Lipp E, Friedman A, Friedman H, Bigner D

3:25-3:30pm
ACTR-49 Phase 1 safety study of BLZ-100 for fluorescence-guided resection of glioma in adult subjects
Miller D, Patil C, Walker D, Kittle D, Nufer K, Yamada M, Butte P, Prow T, Novak J, Black K, Mamelak A

MAIN MEETING PROGRAM

Friday, November 18, 2016

3:30-3:35pm ACTR-15	A Phase I study of the oncolytic virus DNX-2401 and a short course temozolomide for glioblastoma at first recurrence <i>Tejada S, Diez Valle R, Gallego J, Alonso MM, Peterkin J</i>	4:05-4:10pm ATIM-13	Phase I study of chimeric antigen receptor-engineered T cells targeting IL13R α 2 for the treatment of glioblastoma <i>Brown C, Alizadeh D, Starr R, Weng L, Wagner J, Naranjo A, Blanchard S, Kilpatrick J, Simpson J, Ressler J, Jensen M, Portnow J, D'Apuzzo M, Barish M, Forman S, Badie B</i>
3:35-3:40pm ATIM-05	Complementary clinical and ancillary data from 123 patients with recurrent high grade glioma from three Phase 1 trials of Toca 511 and Toca FC: Update and justification for a Phase 2/3 trial <i>Aghi M, Vogelbaum M, Kalkanis S, Bota D, Carter B, Chen C, Elder B, Engh J, Goldlust S, Kaptain G, Kesari S, Landolfi J, Liau L, Mikkelsen T, Piccioni D, Portnow J, Singer S, Walbert T, Gruber H, Ibañez C, Jolly D, Mitchell L, Ostertag D, Shorr J, Yang L, Das A, Cloughesy T</i>	4:10-4:15pm ATIM-28	A phase 1a/1b, multi-center, open-label dose finding study to assess the safety, tolerability and efficacy of the pleiotropic pathway modifier CC-122 administered orally to patients with glioblastoma multiforme (GBM) and other brain tumors <i>Simonelli M, Sepulveda J, Brandes A, Soria J-C, Edenfield J, Moreno V, Gallego Pérez-Larraya J, Britten C, Cloughesy TF, Martinez Garcia M, Balana C, Hagner P, Li Y, Wei X, Gandhi A, Pourdehnad M, Lopez Martin JA, Santoro A, Shih K</i>
3:40-3:45pm ACTR-20	Initial results of PLX108-08: An open label Phase 1b/2 study of orally administered pexidartinib (PLX3397) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma <i>Colman H, Raizer J, Walbert T, Plotkin S, Chamberlain M, Wong E, Puduvalli V, Reardon D, Iwamoto F, Johnson B, Sonty K, Welbourn B, Karlin D, Pelayo M, Hutchinson M, Hsu H</i>	4:15-4:20pm ATIM-31	Allogeneic tumor lysate / autologous dendritic cell vaccines in newly diagnosed glioblastoma: Clinical trial MC1272 <i>Parney IF, Gustafson MP, Peterson T, Steinmetz SM, Bulur P, Dietz AB</i>
3:45-3:50pm ACTR-50	Marizomib (MRZ) with bevacizumab (BEV) in WHO grade IV malignant glioma (G4 MG): Full enrollment results from the phase 1, multicenter, open-label study <i>Bota D, Desjardins A, Mason W, Fine H, Kesari S, Reich SD, Vashishtha A, Levin N, Trikha M</i>	4:20-4:25pm ATIM-11	Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets IL-13R α 2, EphA2, and Survivin, in adults with second-line recurrent GBM: Interim results <i>Reardon D, Peereboom D, Nabors B, Fink K, Phuphanich S, Mikkelsen T, Dunbar E, Badriddojo M, Schiff D, Lieberman F, Tran D, Schulner M, Butowski N, Ashby L, Moertel C, Iwamoto F, Sherman J, Chen J, McDonald P, Poradosu E, Brooks C, Shemesh S, Raizer J</i>
3:50-3:55pm ACTR-04	Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion, an intergroup trial <i>van den Bent M, Vogelbaum M, Erridge S, Nowak A, Sanson M, Brandes AA, Wick W, Clement P, Baurain F, Mason W, Wheeler H, Chinot O, Weller M, Golfopoulos V, Aldape K, Dubbink H, Wesseling P, Gorlia T, Baumert B, Kros J</i>	4:25-4:30pm ATIM-32	Phase IIa clinical trial evaluating dendritic cell vaccine for the treatment of low-grade gliomas <i>Moughon D, Everson R, Odesa S, Soto H, Billingslea-Yoon E, Sedighim S, Orpilla J, Lin J, Prins R, Liau L</i>
3:55-4:00pm ACTR-32	A prospective phase II study of everolimus for recurrent adult low grade gliomas <i>Wahl M, Chang S, Phillips J, Costello J, Mazor T, Molinaro A, Lupo J, Nelson S, Berger MS, Prados M, Butowski N, Taylor J, Clarke J, Haas-Kogan D</i>	4:30-4:35pm ATIM-08	Survival and efficacy data for patients with glioblastoma treated with ipilimumab in combination with bevacizumab <i>Carter T, Brown N, Shaw H, Chester K, Cohn-Brown D, Mulholland P</i>
4:00-4:05pm ACTR-54	Phase I trial of genetically modified hematopoietic progenitor cells facilitating bone marrow chemoprotection and enabling TMZ/O6BG dose escalation resulting in improved survival <i>Sloan A, Fung H, Reese-Kroc J, Rogers L, Murphy C, Lazrus H, Dropulic B, Gerson S</i>	4:35-4:40pm ATIM-19	Categorizing immune responders with fusion metrics and simulation for association to survival and progression free survival with immune response in HLA-A2+ patients with GBM from a phase 2 trial of dendritic cell (DC) immunotherapy (ICT-107) <i>Santos R, Pinilla C, Swanson SJ, Gringeri A, Yu J</i>

MAIN MEETING PROGRAM

Friday, November 18, 2016

4:40-4:45pm
ATIM-25
Ten-year follow up with long term remission in patients with newly diagnosed glioblastoma (GBM) treated with ICT-107 vaccine (phase I)
Phuphanich S, Wheeler C, Rudnick J, Hu J, Mazer M, Sanchez C, Nuno M, Chu R, Black K, Yu J

4:45-4:50pm
ATIM-27
Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide maintenance in recurrent CNS lymphoma
Rubenstein J, Fraser E, Formaker P, Chi-Chiang Lee J, Chen N, Kock M, Cheung W, Killea P, Choi K-H, Wang X, Munster P, Damato B

4:50-5:00pm
Discussion

CONCURRENT SESSION 3B

Pre-Clinical Immunology (Tumor Biology I)

Moderators: Peter Fecci, Marcela Maus

3:15-3:30pm
Invited Speaker: Duane Mitchell

3:30-3:40pm
IMST-14
IDH1 R132H mutation inhibits anti-glioma immune responses through post-transcriptional down-regulation of STAT1 and type-1 chemokines
Kohanbash G, Shrivastav S, Ahn B, Carrera D, Jahan N, Bepler C, Amankulor N, Costello JF, Okada H

3:40-3:50pm
IMST-47
Identification and expansion of glioma-specific T cells using TCR V β expression
Flores C, Wildes T, Drake J, Dyson K, Mitchell D

3:50-4:00pm
IMST-49
Mechanism and therapeutic targeting of osteopontin-mediated immune suppression in GBM
Wei J, Marisetty A, Kong L-Y, Gabrusiewicz K, Hashimoto Y, Ling X, Zhou S, Fuller G, Heimberger A

4:00-4:10pm
EPID-06
Protein-specific antibody responses to Varicella virus identifies lower reactivity to glycoprotein E in prediagnostic sera from glioma cases compared to controls in the PLCO Cohort
Wiemels J, Zhou M, McCoy L, Hansen H, Francis S, Wiencke J, Wrensch M, Bracci P

RAPID REPORTS

4:10-4:15pm
IMST-34
Immunological changes during tumor progression from primary to recurrent glioblastoma
Herold-Mende C, Rapp C, Warta R, Dettling S, von Deimling A, Unterberg A

4:15-4:20pm
IMST-05
Novel CAR-T cells targeting the extracellular matrix of glioblastoma induce strong anti-tumor immune response
Sengupta S, Mohan N, Chiocca EA, Sampath P, Viapiano M

4:20-4:25pm
IMST-38
CAR T cells induce complete regression of murine glioblastoma after preconditioning hosts with temozolomide
Suryadevara CM, Chongsathidkiet P, Riccione K, Gedeon PC, Desai R, Choi BD, Snyder DJ, Li Q-J, Fecci PE, Sanchez-Perez L, Sampson JH

4:25-4:30pm
IMST-44
Lymphopenia enhances the efficacy of CAR T cells delivered loco-regionally in the brain for the treatment of glioblastoma
Suryadevara CM, Desai R, Snyder DJ, Li Q-J, Fecci PE, Sanchez-Perez L, Sampson JH

4:30-4:35pm
IMST-36
Development of murine IL13R α 2-targeted CAR T cells (mIL13BB ζ) for assessment of CAR T cell therapy in syngeneic glioma models
Alizadeh D, Yang X, Wright S, Chang W-C, Forman S, Brown C

4:35-4:40pm
IMST-09
Identification of a novel H3.3.K27M mutation-derived neoantigen epitope and cloning of a specific T-cell receptor for T-cell therapy in gliomas
Kohanbash G, Chheda Z, Sidney J, Okada K, Shrivastav S, Carrera D, Liu S, Jahan N, Mueller S, Pollack I, Carcaboso A, Sette A, Hou Y, Okada H

4:40-4:45pm
IMST-56
Tumor lysate-pulsed DC vaccination induces neoantigen-specific T cell responses
Everson R, Shin N, Antonios J, Soto H, Tucker A, Zaretsky J, Orpilla J, Rathe S, Popescu F, Largaespada D, Liau L, Prins R

4:45-4:50pm
IMST-25
CD70—A novel target of CAR-T-cell therapy for gliomas
Jin L, Ge H, Yang C, Long Y, Chang Y, Mu L, Sayour E, De Leon G, Wang Q, Yang J, Drake J, Kubilis P, Bao H, Xia S, Lu D, Kong Y, Hu L, Yin Y, Shang Y, Jiang C, Nie J, Li S, Qi J, Gu Y, Sun J, Lin Z, Mitchell D, Huang J

4:50-5:00pm
Discussion

CONCURRENT SESSION 3C

Radiation Therapy

Moderators: Michelle Kim, Tony Wang

3:15-3:30pm
Invited Speaker: Christina Tsien

3:30-3:45pm
RTHP-31
Low grade glioma malignant transformation (MT): clinical outcomes and prognostic factors in temozolomide era
Murphy E, Leyrer CM, Parsons M, Suh J, Chao S, Yu J, Jia X, Peereboom D, Stevens G, Ahluwalia MS

MAIN MEETING PROGRAM

Friday, November 18, 2016

RAPID REPORTS

3:45-3:50pm
RTHP-05

Intraoperative Radiotherapy (IORT) using low-energy x-rays in a cohort of predominantly incompletely resected newly diagnosed glioblastoma multiforme (INTRAGO trial)
Giordano FA, Brehmer S, Mürle B, Welzel G, Sperk E, Keller A, Abo-Madyan Y, Clausen S, Schneider F, Herskind C, Seiz-Rosenhagen M, Groden C, Schmiedek P, Glas M, Hänggi D, Petrecca K, Wenz F

3:50-3:55pm
RTHP-10

Phase II study of hypo vs. conventional -fractionated radiotherapy with temozolomide in newly diagnosed glioblastoma: early compliance and tolerance
Mallick S, Haresh KP, Gupta S, Sharma D, Julka P, Rath GK

3:55-4:00pm
BMET-24

Laser ablation after stereotactic radiosurgery (LAASR) – results of a multi-center prospective study
Chiang V, Dietrich J, Tatter S, Mohammadi A, Leuthardt E, Chamoun R, Judy K, Barnett G, Ahluwalia M

4:00-4:05pm
RTHP-27

Phase I/II study of DDFPe as a radiosensitizer in glioblastoma
Unger E, Mason R, Zhou H, Sellenger M, Ruben J, Lickliter J, Longacre O

4:05-4:10pm
RTHP-20

Evaluation of radiation therapy technology and dosimetry impact on treatment outcome for glioblastoma patients
af Rosenschold PM, Law I, Engelholm SA, Muhic A, Lundemann M, Roed H, Grunnet K, Skovgaard Poulsen H

4:10-4:15pm
RTHP-07

Impact of radiotherapy and gross-total resection for ependymoma in young children: a population-based study
Snider C, Yang K, Mack S, Suh J, Chao S, Murphy E

4:15-4:20pm
BMET-22

Does whole brain radiotherapy for oligometastatic brain metastases translate into a survival benefit for patients with a limited competing risk from extra-cranial disease? A secondary analysis of EORTC 22952-26001
Churilla T, Handorf E, Collette S, Collette L, Dong Y, Aizer A, Alexander B, Kocher M, Weiss S, Soffiotti R

4:20-4:25pm
BMET-17

The prognostic role of tumor volume in the outcome of patients with single brain metastasis after stereotactic radiosurgery
Bennett E, Vogelbaum M, Barnett G, Angelov L, Chao S, Murphy E, Yu J, Suh J, Jia X, Elson P, Stevens G, Ahluwalia MS, Mohammadi A

4:25-4:30pm
RTHP-25

Superior prognostic value of cumulative intracranial tumor volume (CITV) relative to largest intracranial tumor volume (LITV) for stereotactic radiosurgery treated brain metastasis patients
Chen C, Hirshman B, Wilson B, Amaan M, Proudfoot J, Koiso T, Nagano O, Serizawa T, Yamamoto M

4:30-4:35pm
BMET-36

Optimal radiosurgery dose for treatment of melanoma and renal cell carcinoma metastases
Hirshman B, Wilson B, Ali MA, Proudfoot J, Koiso T, Nagano O, Serizawa T, Yamamoto M, Carter B, Chen C

4:35-4:40pm
RTHP-03

Gene expression landscape including miRNAs in delayed radiation necrosis of brain
Miyatake S-I, Toho T, Fujita M, Furuse M, Kawabata S, Kuroiwa T, Nonoguchi N

4:40-4:45pm
RTHP-18

Liquid biopsy distinguishes recurrent GBM from radiation necrosis in peripheral blood of patients with GBM
Soler D, Young A, Cooper K, McCormick T, Sloan A

4:45-5:00pm

Discussion

5:30-7:30pm

Industry Supported Symposium

Not sponsored by The University of Texas MD Anderson Cancer Center

- Stereotactic radiosurgery developments in the treatment of brain metastases

7:30-9:30pm

E-TALKS Interactive Electronic 3 Minute Presentations Followed By Group Discussions

7:30-8:15pm

Group 1: Immunology (Preclinical), Tumor Microenvironment, Metabolomics, Oncolytic Viruses

8:25-9:00pm

Group 2: Clinical

Group discussions following each session on interactive flat screens

7:30-9:30pm

POSTER SESSION Traditional Poster Viewing

MAIN MEETING PROGRAM

Friday, November 18, 2016

7:30-9:30pm

E-TALKS

Immunology (Preclinical), Tumor Microenvironment, Metabolomics, Oncolytic Viruses

Moderators: Maria Castro, Balveen Kaur

- 7:30pm
IMST-48 Priming of host T cell memory is required for the efficacy of adoptive cell therapy
Flores C, Abraham R, Mitchell D
- 7:33pm
IMST-11 Downregulation of sphingosine-1-phosphate receptor type 1 mediates bone marrow T-cell sequestration in patients and mice with glioblastoma
Chongsathidkiet P, Farber SH, Woroniecka K, Elsamadicy AA, Cuic X, Fecci P
- 7:36pm
IMST-42 First proof-of-principle study of a novel minimally invasive blood-based diagnostic tool for glioma
van den Bossche W, Vincent A, Orfao A, Dirven C, Lamfers M, van Dongen J
- 7:39pm
METB-02 Expression level of glutaminase 2 is associated with regional heterogeneity of 5-aminolevulinic acid fluorescence in glioblastoma
Park C, Kim SJ, Kim JE, Kim YH, Hwang T, Han JH, Kim K-J, Lee S-T, Kim TM, Choi SH, Park S, Lee S-H
- 7:42pm
CBIO-07 Lipid droplets, a novel diagnostic biomarker and metabolic target in glioblastoma
Geng F, Cheng X, Wu X, Cheng C, Guo JY, Horbinski C, Kaur B, Chakravarti A, Guo D
- 7:45pm
TMIC-10 An IL-1 β /IL-1R pro-tumorigenic signaling loop in glioblastoma
Kaluzova M, Gutmann D, Hambardzumyan D
- 7:48pm
METB-05 Identification of a prognostic sexual dimorphism in glioma glycolysis
Ippolito J, Luo J, Chinnaiyan P, Rubin J
- 7:51pm
EXTH-23 Preclinical analysis of combinatorial glioblastoma therapy with the prodrug-mediated gene therapy vector Adv-tk and immune checkpoint inhibition
Speranza MC, Kasai K, Ricklefs F, Klein SR, Passaro C, Hiroshi N, Kaufmann J, Bronisz A, Aguilar-Cordova E, Guzik BW, Freeman GJ, Reardon DA, Wen P, Chiocca EA, Lawler SE
- 7:54pm
TMIC-14 Tumor evolution of glioma intrinsic gene expression subtype associates with immunological changes in the microenvironment
Wang Q, Hu X, Muller F, Kim H, Squatrito M, Mikkelsen T, Scarpace L, Barthel F, Lin Y-H, Satani N, Martinez-Ledesma E, Chang E, Olar A, Hu B, deCarvalho A, Eskilsson E, Zheng S, Heimberger A, Sulman E, Nam D-H, Verhaak R

7:57pm
TMIC-15

Mutant IDH1 suppresses the procoagulant and promalignant effects of Tissue Factor in gliomas

Unruh D, Mirkov S, James CD, Horbinski C

8:00pm
EXTH-37

Chemotherapy-induced metabolic stress in IDH1 mutant gliomas

Tateishi K, Wakimoto H, Higuchi F, Miller J, Koerner MVA, Lelic N, Shankar G, Tanaka S, Curry WT, Fisher DE, Batchelor TT, Iafrate AJ, Chi AS, Cahill DP

8:03pm
IMST-33

Enhanced T cell activation using dendritic cells pulsed with chimeric RNAs encoding full-length LAMP-1 fusion constructs

Yang C, Dechkovskaia A, Drake J, Guimaraes F, Kubilis P, Huang J, Mitchell D

8:06pm
EXTH-40

M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma

Forsyth P, Kenchappa R, McKenzie B, Pisklakova A, Tran ND, McFadden G

8:09pm
IMST-39

IDO1 is prognostic for glioblastoma patient survival and centrally correlates with potentially immunosuppressive mediators

Zhai L, Genet M, Ladomersky E, Lauing K, Wu M, Binder D, Kim L, Rich J, Horbinski C, James CD, Sosman J, Bloch O, Wainwright D

8:12pm
TMIC-23

Differential expression of therapeutic targets across tumor microenvironments and at infiltrative margins in glioblastoma

Ross J, Brat D, Hadjipanayis C, Cooper L, Williams M, Bouras A, Kaluzova M, Dunn W, Gutman D, Duong D, McCrary M

8:15-8:25pm

GROUP 1 TRANSITIONS TO FLAT SCREENS FOR Q&A

Clinical

Moderators: Marcos Maldaun, Mark Rosenthal

8:25pm
DRES-04

Tumor heterogeneity contributes to resistance to anti-EGFR therapy in glioblastoma

Zanca C, Furnari F

8:28pm
QLIF-21

Quality of life domains in relation to glioma grade

Bracci P, Chang S, Clarke J, Claus E, Lachance D, Luks T, McCoy L, Molinaro A, Taylor J, Wiemels J, Wiencke J, Wrensch M

MAIN MEETING PROGRAM

Friday, November 18, 2016

7:30-9:30pm

E-TALKS

8:31pm
ACTR-12

Phase I/II study of single agent Ibrutinib in recurrent/ refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
Grommes C, Gavrilovic I, Kaley T, Nolan C, Omuro A, Wolfe J, Pentsova E, Hatzoglou V, Mellinghoff I, DeAngelis L

8:58pm
MPTH-39

Sex-specific analysis of GBM transcriptomes reveals new prognostically important molecular subtypes
Yang W, Warrington N, Luo J, Rubin J

8:34pm
DRES-01

Bone marrow response as a potential biomarker of outcomes in glioblastoma patients
Vaios E, Nahed B, Muzikansky A, Fathi A, Dietrich J

9:01-9:10pm

GROUP 2 TRANSITIONS TO FLAT
SCREENS FOR Q&A

8:37pm
DRES-02

Young adult patients with anaplastic glioma may not benefit from radiation plus TMZ treatment compared to radiation only
Pei Y

8:40pm
SURG-18

Real-time intraoperative molecular diagnosis and surgical guidance using laser spectroscopy
Vaqaas B, O'Neill K, Short M, Zeng H, Patel I, Faiz U

8:43pm
BMET-13

Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients with ALK-rearranged (ALK+) NSCLC and baseline brain metastases (BM): Results from ASCEND-1 and -3
Mehra R, Felip E, Shao-Weng Tan D, Kim D-W, Orlov S, Park K, Yu C-J, Mok T, Nishio M, Scagliotti GV, Spigel DR, Sutradhar S, Cesic D, Tsang Shaw A

8:46pm
RTHP-14

Treatment results of stereotactic radiotherapy and bevacizumab (SRT-Bv) for recurrent glioblastoma
Yasuda T, Nitta M, Maruyama T, Tsuduki S, Muragaki Y, Kawamata T

8:49pm
MPTH-26

CXCL13 and IL-10 in cerebrospinal fluid (CSF) as an important biomarker for primary central nervous system cell lymphoma (PCNSL)
Sasayama T, Tanaka K, Nishihara M, Nagashima H, Mizukawa K, Sakata J, Maeyama M, Kohmura E

8:52pm
SURG-14

Operative mortality rates of acoustic neuroma surgery: a nationwide cancer database analysis
McClelland III S, Kim E, Murphy JD, Thomas Jr CR, Jaboin JJ

8:55pm
MPTH-01

Are mutations in mismatch repair (MMR) genes our next biomarker of alkylating agent induced hypermutator phenotype? Preliminary results from the IVY precision trial
Kuhn J, Chen R, Clarke J, Chang S, Cloughesy T, Colman H, Wen P, Mellinghoff I, Ligon K, de Groot J, Batchelor T, Omuro A, Taylor J, Butowski N, Halperin R, Tran N, Carpten J, Craig D, Byron S, Berens M, Prados M

MAIN MEETING PROGRAM

Saturday, November 19, 2016

7:00-9:00am LIGHT CONTINENTAL BREAKFAST

7:00-8:30am **SUNRISE SESSIONS**

Immune Based Therapies for Gliomas

Gavin Dunn, David Reardon (Co-chairs)

- Targeting glioma neoepitopes with specific vaccines
Michael Platten
- Immune checkpoint inhibitors
David Reardon
- CART cells for EGFRvIII+ glioblastoma
Marcela Maus
- Immunotherapy and non-immunotherapy combinations
Michael Weller
- Immunosuppression in glioma
Peter Fecci
- Biomarkers of response to immunotherapy
Gavin Dunn

Biology of Brain Metastases

Priscilla Brastianos, Patricia Steeg (Co-chairs)

- Antiangiogenic prevention and therapy of brain metastases
Frank Winkler
- Genomic evolution of brain metastases
Priscilla Brastianos
- Brain metastasis microenvironment: Insights in the biology that inspires novel therapies
Manuel Valiente
- Immune microenvironment in brain metastases
Anna Sophie Berghoff
- Investigation of the molecular underpinnings of the blood-tumor barrier permeability in brain metastasis models
Brunilde Gril

Circulating Biomarkers/Liquid Biopsy

Bob Carter (Chair)

- Circulating tumor cells in glioma patients
Brian Nahed
- Circulating DNA as a biomarker in human glioma
Chetan Bettegowda
- Identifying potential EV biomarkers for glioma and role of EV in glioma microenvironment
Agnieszka Bronisz
- Extracellular vesicles as biomarkers in human glioma
Bob Carter

Current Update on the Diagnosis and Management of Low Grade Gliomas

Mitchel Berger, Ali Choucair (Co-chairs)

- Imaging in low grade glioma
Ali Choucair
- The surgical management of low-grade gliomas
Mitchel Berger
- The neuropathology and molecular markers associated with low-grade gliomas
Dan Brat
- The neuro-oncological management of low-grade gliomas
Jan Buckner
- Immunotherapy clinical trials for low-grade gliomas
Wolfgang Wick

Glioma Stem Cells and Epigenetics - from Biology to Treatment

Ichiro Nakano, Mario Suvà (Co-chairs)

- Genetic and non-genetic determinants of single-cell programs in human gliomas
Mario Suvà
- The drivers of oncogenesis of glioma stem cells
Antonio Iavarone
- Phenotype switching and not hierarchy contributes to therapy resistance in human glioblastoma
Robert Bachoo
- Population dynamics among heterogeneous cells within a tumor
Ichiro Nakano

Neurofibromatosis

Jaishri Blakely, Scott Plotkin (Co-chairs)

- Impact of NF1 status on glioma pathology
Fausto Rodriguez
- Impact of NF1 on glioma natural history
Nicole Ullrich
- Impact of NF1 status on treatment outcomes for glioma
Roger Packer

MAIN MEETING PROGRAM

Saturday, November 19, 2016

8:30-12:00pm SNO PLENARY SESSION

8:30-8:35am **Introduction of Keynote Speakers**

8:35-9:05am **Keynote Presentation:** The parallel lives of mutations and epimutations during tumor evolution
Joseph Costello

9:05-9:35am **Keynote Presentation:** Epigenetic mechanisms of glioma initiation and evolution
Bradley Bernstein

Top Scoring Abstracts

Moderators: Manish Aghi, Tracy Batchelor

9:35-9:45am Transformation of tumor endothelial cells to mesenchymal stem cell-like cells induces therapy resistance in glioblastoma
ANGI-01 *Huang M, Fan Y*

9:45-9:55am Redefining the cellular architecture of adult and pediatric glioblastomas through large-scale single-cell analyses
GENT-16 *Filbin M, Tirosch I, Neftel C, Hovestadt V, Venteicher A, Hebert C, Shaw M, Escalante L, Pelton K, Goumnerova L, Czech T, Slavic I, Monje M, Bandopadhyay P, Nahed B, Curry W, Cahill D, Louis D, Ligon K, Golub T, Regev A, Suva M*

9:55-10:05am 18FET-PET uptake dynamics serves as an additional imaging biomarker in astrocytomas with IDH1/2 mutation and no LOH1p/19q
NIMG-34 *Suchorska B, Kraus T, Biczok A, Weller M, Unterrainer M, Schüller U, Schmid-Tannwald C, Bartenstein P, Giese A, Albert N, Tonn J-C*
EANO TRAVEL GRANT WINNER

10:05-10:15am Translatable RNA nanoparticles supplant dendritic cell vaccines in cellular immunotherapy
IMST-16 *Sayour E, De Leon G, Pham C, Grippin A, Flores C, Mitchell D*

10:15-10:30am BREAK

10:30-10:45am **Victor Levin Award Introduction:** *Victor Levin*

Victor Levin Recipient: *David Louis*

10:45-11:10am **Presidential Address:** *E. Antonio Chiocca*

- Lifetime Achievement Award: *Margaret Wrensch*
- Public Service Award: *Mary Lovely*

11:10-11:30am **State of SNO:** *J. Charles Haynes*

11:30-12:00pm **Special Keynote:** Pulitzer Prize Winning Author Siddhartha Mukherjee
Supported by Novocure

12:15-1:15pm LUNCH

LUNCHTIME TUTORIALS AND EDUCATIONAL SESSIONS

Not sponsored by The University of Texas MD Anderson Cancer Center

Meet the Editors

Patrick Wen (Neuro-Oncology), Linda Liau (Journal of Neuro-Oncology), Susan Chang (Neuro-Oncology Practice)

Non-coding RNA in Neuro-Oncology

Daniel Lim (Chair)

- Long noncoding RNAs (lncRNAs) as therapeutic targets for glioma, *Daniel Lim*
- The role of non-coding RNAs in the adaptation to tumor microenvironment, *Jakub Godlewski*
- MicroRNAs in gliomas, *Benjamin Purow*

2016 WHO Classification of Medulloblastoma

Stefan Pfister (Chair)

- Medulloblastoma – a diagnostic neuropathologist's view of the new WHO classification, *David Ellison*
- Implications of medulloblastoma subgrouping for surgical aggressiveness, *Michael Taylor*
- Genetic and epigenetic landscape of medulloblastoma subgroups, *Paul Northcott*
- Clinical trials based on medulloblastoma subgroups, *Stefan Pfister*

MAIN MEETING PROGRAM

Saturday, November 19, 2016

12:15-1:15pm LUNCH, continued

Palliative Neuro-Oncology

Tobias Walbert (Chair)

- Palliative care and hospice medicine in neuro-oncology, *Tobias Walbert*
- Symptom management in patients with brain tumors, *Andrea Pace*
- Advance care planning and decision making in neuro-oncology, *Deborah Forst*

Industry Supported Symposia

Not sponsored by The University of Texas MD Anderson Cancer Center

- Anticipating the promise of immunotherapy in GBM
- Live from Scottsdale - FAQs and best practices in the management of glioblastoma

1:30-5:00pm **CONCURRENT SESSIONS**

CONCURRENT SESSION 5A

Angiogenesis/Invasion/Tumor Microenvironment (Tumor Biology II)

Moderators: John de Groot, Erwin Van Meir

1:30-1:45pm Invited Speaker: *Rolf Bjerkvig*

1:45-2:00pm Targeting carcinoma–astrocyte gap junctions
TMIC-02 in brain metastasis
Boire A, Chen Q, Daras M, Kaley T, Patel K, DeAngelis L, Massagué J

2:00-2:15pm New pericytes in glioblastoma (GBM) blood-
ANGI-02 vessels originate from a previously
unrecognized, pericyte progenitor-like cell
Glass R, Tonn J-C, Synowitz M, Taylor V, Kaelin R

2:15-2:25pm Identity and gene profile of tumor-associated
TMIC-06 macrophages in glioblastoma
Chen Z, Feng X, Nie K, Pong W, Rasmussen R, Gutmann D, Hambardzumyan D

2:25-2:35pm An inflammation response gene signature is
TMOD-31 associated with prognosis of glioma patients
with 1p/19q co-deletion tumors
Hu X, Martinez-Ledesma E, Zheng S, Kim H, Barthel F, Jiang T, Hess KR, Verhaak R

2:35-2:45pm Distinct molecular signatures of microglia and
TMIC-29 bone-marrow macrophages in the glioma
perivascular niche
Muller S, Kohanbash G, Liu S, Carrera D, Aghi M, Lim D, Okada H, Diaz A

2:45-2:55pm microRNA inhibition of endothelial DNA
ANGI-09 repair capacity as a glioblastoma therapeutic
strategy
Chen C, Wilson RA, Kanner N, Espinosa-Diez C, Advani S, Li J, Khan O, Franovic A, Weis S, Anderson D, Cheresch D, Anand S

RAPID REPORTS

2:55-3:00pm Role of microglia in the early steps of the
TMIC-18 brain metastatic cascade
Berghoff A, Feinauer, Solecki G, Grosch J, Osswald M, Gil B, Wilhelm D, Raiky U, Hainfellner J, Steeg P, Birner P, Preusser M, Wick W, Winkler F

3:00-3:05pm Glioblastoma-associated myeloid cells display
TMIC-04 nonpolarized M0 macrophage phenotype
Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy L, Maiti S, Thomas G, Zhou S, Wang Q, Elakkad A, Liebelt B, Yaghi N, Ezhilarasan R, Huang N, Weinberg J, Prabhu S, Rao G, Sawaya R, Langford L, Bruner J, Fuller G, Bar-Or A, Li W, Colen R, Curran M, Bhat K, Antel S, Cooper L, Sulman E, Heimberger A

3:05-3:15pm Discussion

CONCURRENT SESSION 5B Neuro-Imaging

Moderators: Ray Huang, Sabrina Ronen

1:30-1:40pm Invited Speaker: Brain tumor imaging as
prognostic marker in gliomas-the clinician's
perspective:
Joerg-Christian Tonn

1:40-1:50pm Radiological response assessment in the era
NIMG-13 of bevacizumab: RANO or volumetry? A
report from the BELOB trial
Gahrmann R, van den Bent M, van der Holt B, Vernhout R, Taal W, Taphoorn M, de Groot JC, Beerepoot L, Buter J, Flach Z, Hanse M, Jasperse B, Smits M

1:50-2:00pm Residual enhancing tumor volume is a strong
NIMG-31 prognostic biomarker for survival in both
newly diagnosed and recurrent GBM
regardless of therapy: Evidence from 1,535
patients in single and multicenter trials
Ellingson B, Abrey L, Garcia J, Chinot O, Aftab D, Schwab G, Revil C, Saran F, Nishikawa R, Henriksson R, Hessel C, Harris R, Woodworth D, Leu K, Lai A, Sahebjam S, Pope W, Mason W, Wick W, Wen P, Cloughesy T

MAIN MEETING PROGRAM

Saturday, November 19, 2016

2:00-2:10pm
NIMG-12 Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response
Kickingereder P, Götz M, Muschelli J, Wick A, Neuberger U, Shinohara RT, Sill M, Nowosielski M, Schlemmer H-P, Radbruch A, Wick W, Bendszus M, Maier-Hein KH, Bonekamp D

RAPID REPORTS

2:10-2:15pm
NIMG-33 Prognostic value of contrast enhancement and histopathological grading in diffuse gliomas depends on IDH1/2 mutation
Suchorska B, Biczok A, Lenski M, Albert N, Schmid-Tannwald C, Schüller U, Tonn J-C

2:15-2:20pm
NIMG-11 Highly-expressed wild-type EGFR and EGFRvIII mutant glioblastomas have similar MRI signature, consistent with deep peritumoral infiltration
Bakas S, Binder ZA, Akbari H, Martinez-Lage M, Rozycki M, Morrisette JD, Dahmane N, O'Rourke DM, Davatzikos C

2:20-2:25pm
NIMG-05 Radiogenomics to characterize regional genetic heterogeneity in glioblastoma
Hu L, Ning S, Eschbacher J, Baxter L, Gaw N, Ranjbar S, Plasencia J, Dueck A, Peng S, Smith K, Nakaji P, Karis J, Quarles C, Wu T, Loftus J, Jenkins R, Sicotte H, Kollmeyer T, O'Neill B, Elmquist W, Hoxworth J, Frakes D, Sarkaria J, Swanson K, Tran N, Li J, Mitchell R

2:25-2:30pm
NIMG-16 Response assessment of bevacizumab therapy for glioblastoma treatment by using 11C-methionine, 18F-fluorothymidine and 18F-fluoromisonidazole PET tracers
Miyake K, Kouchi M, Ogawa D, Okada M, Hatakeyama T, Shinomiya A, Tamiya T

2:30-2:35pm
NIMG-42 Penetration of radiolabeled temozolomide correlates with contrast enhancement in patients with recurrent GBM treated with bevacizumab
Yen Y-F, Da X, Catana C, Ou Y, Hooker J, Kalpathy-Cramer J, Rosen B, Batchelor T, Gerstner E

2:35-2:40pm
NIMG-73 Accurate 3D GBM segmentation in 30 seconds
Mitchell R, Xue W, Swanson K

2:40-2:45pm
NIMG-54 Amine CEST MRI, a fast amino acid and pH-weighted molecular imaging technique, correlates with 18F-FDOPA PET and image-guided biopsy in human glioma
Harris R, Liau L, Leu K, Nghiemphu P, Pope W, Lai A, Cloughesy T, Ellingson B

2:45-2:50pm
NIMG-56 Patterns from dynamic vessel size imaging of arterial and venous perfusion correlates with aggressiveness and stratifies 1p19q co-deleted from non-codeleted low-grade gliomas
Leu K, Cloughesy T, Liau L, Nghiemphu P, Lai A, Pope W, Ellingson B

2:50-2:55pm
NIMG-60 Diffusion imaging interpretation for grade 2 and 3 gliomas depends upon new vs recurrent status and enhancing vs non-enhancing status
Luks T, McKnight T, Neill E, Dayal M, Jalbert L, Williams A, Lobo K, Persson A, Perry A, Cha S, Phillips J, Molinaro A, Chang S, Nelson S, Berger MS

2:55-3:00pm
NIMG-69 Distinguishing radiation necrosis from brain tumor recurrence on routine MRI: A preliminary human-machine reader comparison study
Prasanna P, Nayate A, Gupta A, Rogers L, Singh G, Wolansky L, Pinho M, Hatanpaa K, Madabhushi A, Tiwari P

3:00-3:05pm
NIMG-64 Novel methods for genotype-phenotype correlation in schwannomatosis
Jordan J, Smith M, Merker V, Cai W, Harris G, Bredella M, Erdin S, Gusella J, Plotkin S

3:05-3:15pm Discussion

CONCURRENT SESSION 5C

Pediatrics, Clinical and Biological

Moderators: Mariella Filbin, Theodore Nicolaides

1:30-1:40pm Invited Speaker: Roger Packer

1:40-1:50pm
TMOD-30 R206H ACVR1 significantly accelerates diffuse intrinsic pontine glioma pathogenesis
PEDIATRIC BASIC RESEARCH AWARD
Hoeman C, Hu G, Cordero F, Becher O

1:50-2:05pm
PDTB-20 Preclinical efficacy of ALK2 inhibitors in ACVR1 mutant DIPG
Carvalho D, Taylor K, Olaciregui NG, Valenti M, Ruddle R, Henley A, Hayes A, De Haven Brandon A, MacKay A, Molinari V, Vinci M, Popov S, Brennan P, Moore A, Hudson L, Hoelder S, Bullock A, Raynaud F, Eccles S, Montero Carcaboso A, Jones C

MAIN MEETING PROGRAM

Saturday, November 19, 2016

2:05-2:15pm
PDTB-11

Disrupting the epigenetic modifier HMG2 in lethal pediatric and adult gliomas inhibits invasion, growth and tumorigenicity
Kaur H, Hütt-Cabezas M, Taylor I, Weingart M, Rodriguez F, Eberhart C, Raabe E

2:15-2:25pm
PDCT-09

Hypermutation and neoantigen formation is diagnostic and predict response to immune checkpoint inhibition in childhood biallelic mismatch repair deficient brain tumors
Campbell B, Bouffet E, Larouche V, Mason G, Reddy A, Osborne M, Magimairajan V, Merico D, de Borja R, Chung B, Galati M, Aronson M, Durno C, Krueger J, Cabric V, Zhukova N, Ramaswamy V, Farah R, Afzal S, Yalon M, Rechavi G, Walsh M, Rina D, Ronit E, Sullivan M, Hansford J, Dodgshun A, Klauber-Demore N, Peterson L, Patel S, Lindhorst S, Atkinson J, Laframboise R, Cohen Z, Dirks P, Taylor M, Malkin D, Albrecht S, Dudley R, Jabado N, Hawkins C, Shlien A, Tabori U

2:25-2:35pm
PDTB-13

Detection of histone H3 mutations in pediatric glioma via tumor DNA derived from cerebrospinal fluid
Saratsis A, Huang T, Piunti A, Lulla R, Tomita T, James CS, Shilatifard A

2:35-2:45pm
MPHT-17

PEDIATRIC CLINICAL RESEARCH AWARD

Integrated molecular and pathological characterisation of non-brainstem paediatric high grade glioma from the HERBY phase II randomized trial
Mackay A, Burford A, Molinari V, Jones DTW, Pfister SM, Wurdinger T, Bais C, Das Thakur M, Vassal G, Grill J, Varlet P, Jones C

2:45-2:55pm
PDCT-07

HERBY (BO25041): a phase II open-label, randomized, multicenter, comparative study of bevacizumab (BEV)-based therapy in pediatric patients with newly diagnosed high-grade glioma (HGG)
Grill J, Hargrave D, Massimino M, Bouffet E, Azizi A, McCowage G, Cañete A, Saran F, Le Deley M-C, Varlet P, Morgan PS, Jaspan T, Jones C, Smith H, Garcia J, Hilton M, Rousseau R, Abrey L, Vassal G

2:55-3:05pm
CSIG-10

SHH-Medulloblastoma preferentially arises from granule cell precursors in the lateral cerebellum
Tan I-L, Wojcinski A, Rallapalli H, Volkova E, Remke M, Korshunov A, Turnbull D, Taylor M, Joyner A

3:05-3:15pm
PDCT-15

Re-MATCH: A phase 2 multi-institutional clinical trial of adoptive cellular therapy following myeloablative or non-myeloablative chemotherapy in children and young adults with recurrent medulloblastoma and PNETs
Gururangan S, Sayour E, Cleaver B, Clement N, Pincus D, Slayton W, Fort J, Castillo P, Hodik M, Boyette R, McGrew N, King J, Huang J, Yang C, Dechkovskaia A, Drake J, Mitchell D

CONCURRENT SESSION 6A

Stem Cells (Tumor Biology II)

Moderators: Justin Lathia, Mario Suvà

3:30-3:40pm Invited Speaker: Peter Dirks

3:40-3:50pm
STMC-27

Novel lysine demethylase KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway
Reddy Sareddy G, Viswanadhapalli S, Surapaneni P, Suzuki T, Brenner A, Vadlamudi R

3:50-4:00pm
STMC-06

QKI deletion enhances self-renewal of glioma stem cells and promotes gliomagenesis
Hu J, Shingu T

4:00-4:10pm
STMC-34

Role of Interleukin-8/CXCR2 regulated epigenetic plasticity in GBM recurrence
Hasan T, Atashi F, Kim J, Guo D, Park C, Wu M, Dey M, Lesniak M, Horbinski C, Ahmed A

4:10-4:20pm
STMC-38

EYA1 identified by in vitro and in vivo phage display biopanning demonstrates role in glioblastoma stem cell proliferation through oncogene interaction
Huang P, Wu Q, Rich J, Liu J

4:20-4:30pm
STMC-15

Innate immune signaling via TLR4 suppresses self-renewal in glioblastoma
Lathia J, Alvarado A, Vogelbaum M, Hale J, Silver D

RAPID REPORTS

4:30-4:35
STMC-14

Glioblastoma cancer stem cells undergo dynamic state transitions
Dirkse A, Brons NHC, Buder T, Deutsch A, Leite S, Sauvageot N, Senn S, Herold-Mende C, Golebiewska A, Niclou S

4:35-4:40pm
STMC-16

EZH2-mediated ARL13B regulate ciliogenesis in GBM
Atashi F, Hasan T, Lee G, Guo D, Park C, Lesniak M, James CS, Ahmed A

4:40-4:45pm
STMC-21

Astrocytoma mutations IDH1, p53 and ATRX cooperate to block differentiation of neural stem cells via Sox2
Modrek A, Golub D, Khan T, Zhang G, Kader M, Bowman C, Prado J, Bayin NS, Frenster J, Lhakhang T, Heguy A, Dankert J, Tsirigos A, Snuderl M, Neubert T, Placantonakis D

4:45-4:50pm
STMC-28

Intact EGFR defines human germinal matrix and glioblastoma populations with shared and epigenetically imprinted stem cell properties
Tome-Garcia J, Tejero-Villalba R, Zaslavsky E, Nudelman G, Yong R, Walsch M, Friedel R, Doetsch F, Tsankova N

4:50-5:00pm Discussion

MAIN MEETING PROGRAM

Saturday, November 19, 2016

CONCURRENT SESSION 6B

RANO Update

Moderators: Susan Chang, David Macdonald, Martin van den Bent, Michael Vogelbaum, Patrick Wen

3:30-3:40pm	Brain metastases clinical trial design and endpoints <i>Eudocia Quant Lee, Brian Alexander</i>
3:40-3:47pm	Leptomeningeal disease <i>Marc Chamberlain</i>
3:47- 3:54pm	Pediatrics <i>Mark Kieran</i>
3:54-4:01pm	Meningiomas <i>Patrick Wen, Ray Huang, Michael Vogelbaum</i>
4:01-4:16pm	PET <i>Joerg-Christian Tonn</i>
4:16-4:24pm	iRANO <i>Hideho Okada, David Reardon</i>
4:24-4:32pm	NANO <i>Lakshmi Nayak, David Reardon</i>
4:32-4:39pm	Steroids <i>Patrick Wen, Nils Arvold</i>
4:39-4:46pm	Seizures-the next step <i>Edward Avila</i>
4:46-4:56pm	Patient reported outcomes <i>Martin Taphoorn</i>
4:56-5:06pm	Jumpstarting brain tumor drug development standardization effort <i>Benjamin Ellingson, Mark Gilbert</i>
5:06-5:14pm	Novel endpoints for low grade gliomas <i>Ray Huang</i>
5:14-5:25pm	Challenges in assessing response to therapy in recurrent patients in the post-operative setting <i>Andrew Lassman</i>

CONCURRENT SESSION 6C

Pediatrics, Clinical and Biological

Moderators: Michelle Monje-Deisseroth, Sabine Mueller

RAPID REPORTS

3:30-3:35pm STMC-02	Tumor recurrence from cancer stem-like cells post-radiation is regulated by the Shh-YAP-YB1-IGF2 axis in medulloblastoma <i>Dey A, Malhotra A, Kenney A</i>
------------------------	--

3:35-3:40pm PALL-05	Pediatric brainstem glioma: impact of surgery and radiotherapy on survival outcomes <i>Yang K, Kim L, Recinos V, Suh J, Chao S, Murphy E</i>
3:40-3:45pm PDCT-10	First in pediatrics phase I study of crenolanib besylate (CP-868,596-26) administered during and after radiation therapy (RT) in newly-diagnosed diffuse intrinsic pontine glioma (DIPG) and recurrent high grade glioma (HGG) <i>Wetmore C, Turner D, Kun L, Onar-Thomas A, Huang J, Gajjar A, Baker S, Stewart C, Broniscer A</i>
3:45-3:50pm PDTB-04	Casein kinase 2 regulates expression and activity of MYC in group 3 medulloblastoma <i>Jin B, Nitta R, Li G</i>
3:50-3:55pm TMOD-17	Convergence of BMI1 and CHD7 on ERK signalling in medulloblastoma <i>Marino S, Dubuc A, Da Cunha Jaeger M, Morrissy S, Taylor M, Zhang X</i>
3:55-4:00pm PDTB-09	Organotypic tumor slice culture for evaluating treatment of medulloblastoma <i>Felker J, Dey A, MacDonald T, Kenney A</i>
4:00-4:05pm CBIO-14	Exploring the OTX2 regulatory network: Targeting the “grow and go” arms of the most aggressive medulloblastomas <i>Stromecki M, Kaur R, Tatari N, Morrison L, Skowron P, Taylor M, Werbowetski-Ogilvie T</i>
4:05-4:10pm IMST-17	Phenotype modulation of tumor associated microglia enhances pediatric medulloblastoma cell death in vitro <i>Bredlau A-L, Eskandari R, McDonald DG, Lowe S, Vanek KN, Banik NL, Jenrette III JM, Patel SJ, Cheshier S, Das A</i>
4:10-4:15pm PDTB-21	CD271 (p75NTR) as a novel diagnostic marker and therapeutic target for SHH medulloblastoma <i>Liang L, Coudiere-Morrison L, Tatari N, Remke M, Ramaswamy V, Issaivanan M, Ryken T, Del Bigio M, Taylor M, Werbowetski-Ogilvie T</i>
4:15-4:20pm DDIS-16	A novel epigenetic pathway for the treatment of medulloblastoma <i>Ayad N</i>
4:20-4:25pm PDTB-24	Targeted therapy for leptomeningeal metastasis of medulloblastoma <i>Grausam K, Dooyema S, Zeng E, Zhao H</i>
4:25-4:30pm PDCT-12	Outcomes for non metastatic desmoplastic/nodular infant medulloblastoma treated with reduced intensity chemotherapy and oral maintenance chemotherapy <i>Upadhyaya SA, Robinson G, Orr B, Onar-Thomas A, Billups C, Bowers D, Bendel A, Crawford J, Klimo P, Harrel J, Boop F, Merchant TE, Ellison DW, Gajjar A</i>

MAIN MEETING PROGRAM

Saturday, November 19, 2016

4:30-4:35pm PDCT-13	Guidelines for response assessment in medulloblastoma and other leptomeningeal seeding tumors: A report from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) Working Group <u>Warren K</u> , Harreld J, Chamberlain M, Vezina G, Warmuth-Metz M, von Hoff K, Packer R, Brandes AA, Reiss M, Goldman S, Fisher M, Young Poussaint T, Pollack I, Prados M, Wen P, Chang S, Dufour C, Zurakowski D, Kortman R-D, Kieran M	4:40-4:45pm PDTB-06	Suppression of molecular circuit of multiciliate differentiation is critical for choroid plexus carcinoma development <u>Zhao H</u> , Li L
4:35-4:40pm PDTB-22	The role of the chromosome 19 microRNA cluster (C19MC) in embryonal tumor with multilayered rosettes (ETMR) <u>Chen MJ</u> , Dixit R, Sin-Chan P, Huang A, Chan JA	4:45-4:50pm GENT-31	PedcBioPortal: A cancer data visualization tool for integrative pediatric cancer analyses Raman P, Resnick AC, Storm PB, Mueller S, Schultz N, Cerami E, Maris JM, <u>Waanders AJ</u>
		4:50-5:00pm	Discussion

5:00-7:00pm	E-TALKS Interactive Electronic 3 Minute Presentations Followed By Group Discussions
5:00-5:45pm	Group 1: Epigenetics/Genetics, Tumor Models, Genetically Targeted Experimental Therapeutics
5:55-6:30pm	Group 2: Stem Cell, Cell Biology
	<i>Group discussions following each session on interactive flat screens</i>

5:00-7:00pm	POSTER SESSION Traditional Poster Viewing
7:00-11:00pm	SNO GALA Held at the Scottsdale Airpark Hangar <i>(Separate Ticket Required)</i>

5:00-7:00pm	E-TALKS
-------------	----------------

Epigenetic/Genetic, Tumor Models, Genetically Targeted Experimental Therapeutics

Moderators: Andrew Chi, Elizabeth Maher

5:00pm CBIO-02	Mutant IDH expression drives TERT promoter reactivation as part of the cellular transformation process <u>Ohba S</u> , Mancini A, Mukherjee J, Johannessen T-C, Chow T, Wood M, Jones L, Mazor T, Marshall R, Viswanath P, Hirose Y, Walsh K, Perry A, Bell R, Phillips J, Costello J, Ronen S, Pieper R	5:12pm TMOD-05	Regional astrocyte heterogeneity influences evolution of low-grade glioma during malignant progression <u>Irvin D</u> , Vitucci M, McNeill R, Bash R, Miller CR
5:03pm GENT-08	Human glioblastoma astrocytes resemble fetal astrocyte precursor cells as revealed by immunopanning and RNAseq Zhang Y, Sloan S, Barres B, <u>Hayden Gephart M</u>	5:15pm GENT-12	Molecular grouping of tumors from patients with familial glioma <u>Ruiz V</u> , Armstrong G, Praska C, Kollmeyer T, Yamada S, Decker P, Kosel M, Eckel-Passow J, The GLIOGENE Consortium, Lachance D, Bainbridge M, Melin B, Bondy M, Jenkins R
5:06pm TMOD-04	Naturally occurring canine glioma as a model for novel therapeutics <u>Hubbard M</u> , Arnold S, Bin Zahid A, McPheeters M, Pluhar E, Hunt M	5:18pm GENT-14	Genome wide methylomic and transcriptomic analyses identify epigenetic signatures uniquely dysregulated in GBM subtypes <u>Pangeni R</u> , Alvarez A, Huang T, Zhang W, Zhang Z, Sastry N, Lu S, Kessler J, Brenann C, Sulman E, Lu X, Nakano I, Hu B, Cheng S-Y
5:09pm GENT-11	Small molecule epigenetic screen identifies novel E ZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells <u>Grinshtein N</u> , Rioseco C, Marcellus R, Uehling D, Aman A, Lun X, Muto O, Podmore L, Cairncross G, Robbins S, Jones S, Marra M, Al-awar R, Senger D, Kaplan D	5:21pm EXTH-36	Screening compounds that target the DNA damage response for blood-brain-barrier permeability <u>Dave N</u> , Shannon H, Sinn A, Spragins T Bailey B, Hemenway C, Ding J, Saadatzaheh M, Jones D, Cohen-Gadol A, Pollak K
		5:24pm MNGO-08	Transcriptional characterization of meningioma progression Martinez-Lage M, Thawani J, Zhu Y, Zhang B, Bailey R, Roccograndi L, O'Rourke DM, Resnick AC, Grady MS, <u>Dahmane N</u>

MAIN MEETING PROGRAM

Saturday, November 19, 2016

5:00-7:00pm

E-TALKS

5:27pm
EXTH-50

Specific knockdown of EGFR and PLK1 gene expression in U87 GBM cells with radiofrequency energy (RFE) device
Ulasov I, Ghosh D, Butters M, Butters J, Cobbs C

5:30pm
TMOD-33

Non-Mendelian inheritance of extrachromosomal DNA elements can drive disease evolution in glioblastoma
Kim H, deCarvalho A, Poison LM, Winn M, Mueller C, Cherba D, Koeman J, Seth S, Protopopov A, Felicella M, Zheng S, Zhang J, Petricoin E, Chin L, Mikkelsen T, Verhaak R

5:33pm
EXTH-56

Aromatase expression in high grade gliomas: A potential new target for therapy
Dave N, Sengonkar V, Chow LML, Kendler A, LaSance K, Desai P

5:36pm
GENT-48

Structural variants in gliomas affect regulatory DNA elements and cause ectopic gene expression
Tang M, Lan Z, Amin S, Barthel F, Raman A, Zheng S, Wang Q, Rai K, Sulman E, Verhaak R

5:39pm
RBIO-04

Fractal structure in the volumetric contrast enhancement of malignant gliomas as a marker of oxidative metabolic pathway gene expression
Miller K, Berendsen S, Seute T, Yeom K, Gephardt M, Grant G, Robe P

5:42pm
MPH-36

Comprehensive genomic analysis of young adult glioblastomas reveals four subclasses with distinct driver events
Ramkisson S, Chang M, Johnson A, Gay L, Chmielecki J, Elvin J, Suh J, Fichtenholtz A, Frampton G, Ali S, Stephens P, Miller V, Neumann E, Ross J

5:45-5:55pm

GROUP 1 TRANSITIONS TO FLAT SCREENS FOR Q&A

Stem Cells, Cell Biology

Moderators: Claudia Petritsch, Monica Venere

5:55pm
STMC-03

Repositioning chlorpromazine against chemoresistant glioma through the inhibition of cytochrome c oxidase
Griguer CE, Oliva C

5:58pm
STMC-09

Assessment of tumorigenic potential of human induced pluripotent stem cell-derived neural stem/progenitor cells
Iida T, Iwanami A, Kohyama J, Nagoshi J, Matsumoto M, Okano H, Nakamura M

6:01pm
STMC-29

Genetic engineering of glioma cells with histone-2B-GFP tag to track and characterize quiescent glioma stem cells
Tejero R, Huang Y, Tome-Garcia J, Zou H, Friedel R

6:04pm
CSIG-05

Putting the brakes on Brachyury: Identifying and targeting a conserved transcriptional network that drives primary and metastatic tumor initiation and propagation
Shah S, David J, Tipples N, Mohyeldin A, Martinez JC, Ganaha S, Levchenko A, Palena C, Quinones-Hinojosa A

6:07pm
STMC-17

N-cadherin upregulation mediates slow proliferation and therapeutic resistance in glioma stem
Osuka S, Sampetean O, Onishi N, Saya H, Van Meir E

6:10pm
CBIO-12

Six extracellular vesicle related genes can explain the pro-tumorigenic behavior of heterogeneous high grade gliomas
Ricklefs F, Mineo M, Kumar A Rooj, Chiocci EA, Godlewski J, Bronisz A

6:13pm
CSIG-15

CIC regulates neural stem/progenitor proliferation and differentiation
Tanveer Ahmad S, Rogers AD, Dixit R, Lawn SO, Chen MJ, Adnani L, Alshehri M, Robbins SM, Schuurmans C, Cairncross G, Chan JA

6:16pm
CSIG-20

Identification of a NAMPT-E2F2-ID1 signaling axis in glioblastoma
Gujar A, Turski A, Le S, Mao D, Dadey D, Aum D, Luo J, Hallahan D, Tran D, Yano H, Kim A

6:19pm
CSIG-23

Cytoplasmic RNA Stress Granules: A putative translational mechanism of mTOR regulation in glioblastoma
Weeks A, Whitehouse S, Robichaud A, Agnihotri S, Smith C, Rutka J

6:22pm
STMC-24

Novel inhibitor of CDK5 signaling axis suppresses self-renewal properties of GBM stem cells and induces apoptosis
Mukherjee S, Chau M, Tucker-Burden C, Zhang C, Kong J, Read R, Brat D

6:25pm
STMC-25

GPR133 promotes hypoxia-driven tumor progression in glioblastoma
Frenster J, Bayin NS, Kane JR, Rubenstein J, Modrek A, Baitamal R, Dolgalev I, Rudzenski K, Snuderl M, Golfinos J, Doyle W, Pacione D, Chi A, Heguy A, Shohdy N, MacNeil D, Huang X, Parker E, Zagzag D, Placantonakis D

6:28pm
STMC-37

S100A4 is a critical regulator of stemness and the mesenchymal phenotype in GBMs
Chow K-H, Park HJ, George J, Gallup A, Wood S, Yamamoto K, Neilson E, Graber J, Steindler D, Yun K

6:28-6:38pm

GROUP 2 TRANSITIONS TO FLAT SCREENS FOR Q&A

MAIN MEETING PROGRAM

Sunday, November 20, 2016

7:00-9:00am LIGHT CONTINENTAL BREAKFAST

7:00-8:30am **SUNRISE SESSIONS**

Incorporating Novel Imaging Endpoints in Glioma Trials

Benjamin Ellingson, Patrick Wen (Co-chairs)

- RANO 2.0 updates and proposals
Patrick Wen
- Volumetric and change in tumor growth rate as subclinical endpoints in low grade gliomas
Raymond Huang
- PET-based imaging endpoints
Whitney Pope
- Integration of advanced MR imaging measurements into response assessment
Benjamin Ellingson
- MR spectroscopic imaging endpoints
Sarah Nelson

Cell Signaling as Therapeutic Opportunities

Frank Furnari (Chair)

- Notch pathway inhibition and mechanism of its resistance in glioblastoma stem cells
Xing Fan
- Contextual signaling in brain cancer
David Gutmann
- Tyrosine phosphorylation of nuclear PTEN promotes therapeutic resistance through DNA damage repair
Frank Furnari
- Proteostatic and metabolic control of glioblastoma
Albert Kim

CNS Lymphomas: What have we learned from randomized trials?

Joachim Baehring, James Rubenstein (Co-chairs)

- Randomized trials in Europe
Andrés Ferreri
- Randomized trials in the United States
Antonio Omuro
- Future questions for randomized trials
Lakshmi Nayak

DNA Damage Response in Glioblastoma: Diagnostic and Therapeutic

Clark Chen (Chair)

- DNA damage response in glioblastoma: diagnostic and therapeutic
Viive Howell
- Temozolomide induced genomic instability
Joseph Costello
- Chromosomal instability affects the tumorigenicity of glioblastoma tumor-initiating cells
Kristina Godek
- Genetic basis for clinical response to immunotherapeutic agents
Timothy Chan

AAN & SNO Sponsored Session: Glioma and Neural Networks

Michelle Monje-Deisseroth, Frank Winkler (Co-chairs)

- Astrocytomas exploit neurogenesis pathways to build a functional and resistant multicellular network
Frank Winkler
- Neuronal activity promotes glioma growth
Michelle Monje-Deisseroth
- The brain-glioma interface
Harald Sontheimer
- Identification of diverse astrocytic populations and their emergence during glioma induced seizures
Benjamin Deneen

Surgical Delivery of Therapeutics

Krystof Bankiewicz, Michael Vogelbaum (Co-chairs)

- Convection enhanced delivery for brainstem glioma
Mark Souweidane
- Utility of tracers to evaluate direct drug delivery to the CNS
Michael Vogelbaum
- Clinical trials involving novel agents for CED
Krystof Bankiewicz
- Development of a novel intracavitary drug delivery platform
Colin Watts

MAIN MEETING PROGRAM

Sunday, November 20, 2016

9:00-12:00pm CONCURRENT SESSIONS

CONCURRENT SESSION 7A

Molecular Pathology I

Moderators: Charles Eberhart, Felix Sahm

- 9:00-9:15am Invited Speaker: *Kenneth Aldape*
- 9:15-9:30am GENT-28 The epigenetic landscape of atypical teratoid/ rhabdoid tumors reveals a repressed methylome and epigenetic switches at SMARCB1 binding sites
Erkek S, Johann P, Kerl K, Finetti M, Zapatka M, Fruehwald MC, Chavez L, Gajjar A, Williamson D, Hasselblatt M, Pfister SM, Kool M
- 9:30-9:40am GENT-05 Deletion or amplification of mutant IDH1 is associated with extreme DNA hypomethylation and malignant progression
Mazor T, Jalbert L, Pankov A, Hong C, Hayes J, Smirnov I, Marshall R, Perry A, Nelson S, Chang S, Bollen A, Molinaro A, Bengtsson H, Olshen A, Phillips J, Costello J
- 9:40-9:50am MNGO-13 Germline mutations in individuals with meningioma and breast cancer
Jackson M, Bergner A
- 9:50-10:00am MNGO-11 Report from the Meningioma Consortium: Confirmation of a meningioma risk locus at 10p12
Claus E, Calvocoressi L, Schildkraut J, Walsh K, Hansen H, Smirnov I, McCoy L, Lu L, Ma X, Bondy M, Wrensch M, Wiemels J
- 10:00-10:10am RARE-39 Intravascular lymphoma affecting the central nervous system: features and outcomes in a case series of the Primary CNS Lymphoma Collaborative Group (IPCG)
Zukas A, Bennani N, Chou C, Johnston P, O'Neill BP, Nijland M, Batchelor T, Nayak L, Mrugala M, Low J, Omuro A, Ferreri F, Nishikawa R, Mishima K, Fox C, Wilson W, Houillier C, Chamberlain M, Schiff D
- 10:10-10:20am BMET-06 Improved survival and prognostic ability in lung cancer patients with brain metastases: an update of the Graded Prognostic Assessment for Lung Cancer using molecular markers (Lung-molGPA)
Sperduto P, T. Yang J, Beal K, Pan H, Brown P, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle JM, Kirkpatrick J, Mak K, Shih H, Engelman A, Roberge D, Arvold N, Alexander B, Awad M, Contessa J, Chiang V, Hardie J, Ma D, Lou E, Sperduto W, Mehta M

- 10:20-10:30am RARE-49 Defining relapse patterns in primary CNS diffuse large B-cell lymphoma: A multicenter study
Wang N, Fadul C, Davis M, Nayak L, Baehring J, Batchelor T
- 10:30-10:40am GENT-36 The genomic landscape of schwannoma
Agnihotri S, Wilson M, Jalali S, Danesh A, Li M, Klironomos G, Krieger J, Mansouri A, Khan O, Yasin M, Tonge P, Agarwalla PK, Bi WL, Dunn I, Beroukhi R, Fehlings M, Bril V, Pagnotta S, Pugh T, Iavarone A, Aldape KD, Zadeh G
- 10:40-10:50am IMST-41 Parallel profiling of mutational landscape, gene expression, and T-cell receptor repertoires in subependymoma reveals immunophenotypic heterogeneity
Sims J, Sun X, Wei J, Samanamud J, Neira J, Sawaya R, Fuller G, Heimberger A, Shen Y, Canoll P, Bruce J
- 10:50-11:00am Discussion

CONCURRENT SESSION 7B

Practical and Applied Neuro-Oncology I

Moderators: Martin Taphoorn, Tobias Walbert

- 9:00-9:15am Invited Speaker: Bringing precision to patient management: prediction, prevention, and supportive care in the new era
Terri Armstrong
- 9:15-9:30am QLIF-03 ADULT QUALITY OF LIFE RESEARCH AWARD Mutant IDH1 promotes tumor-associated epilepsy in glioma patients
Chen H, Judkins J, Ghamsari F, Lein P, Horbinski C
- 9:30-9:40am NCOG-14 White matter changes linked to language recovery in adult glioma
Altshuler D, Wang L, Shah G, Kluin K, Brezzell A, Cao Y, Hervey-Jumper SL
- 9:40-9:50am QLIF-07 Health-Related Quality of Life (HRQoL) in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only (randomized phase III EORTC study 26101)
Taphoorn M, Bottomley A, Coens C, Reijneveld J, Gorlia T, Brandes AA, Domont J, Idubai A, van den Bent M, Wick W
- 9:50-10:00am QLIF-25 Physical health risks in neuro-oncology family caregivers
Sherwood P, Marsland A, Donovan H, Weimer J, Armstrong TS, Drappatz J

MAIN MEETING PROGRAM

Sunday, November 20, 2016

10:00-10:10am
NCOG-17 Evaluation of neurocognitive function in patients with cerebellar medulloblastoma
Harrison RA, Johnson JM, Sullaway CM, Wefel JS

10:10-10:20am
PALL-04 Race and gender differences in hospice enrollment of Medicare beneficiaries with primary brain tumors
Dulaney C, Dover L, Jackson B, Rocque G, Fiveash J, Warren P

RAPID REPORTS

10:20-10:25am
QLIF-08 An investigation of brain-tumor related epilepsy in the GliomaSE consortium
Warren P, Nabors B, Peeri N, Thompson Z, Thompson R, Chowdhary S, Olson JJ, LaRocca R, Rozmeski C, Forsyth P, Egan K

10:25-10:30am
SURG-34 Improved survival with decreased wait time to surgery in glioblastoma patients presenting with seizure
Flanigan PM, Jahangiri A, Kuang R, Truong A, Choi S, Chou A, McDermott MF, Berger MS, Agbi M

10:30-10:35am
QLIF-01 Perceived Effectiveness of Management Strategies Used by Neuro-Oncology Family Caregivers
Roberge MC, Hughes SH, Weimer J, Misko S, Armstrong T, Sherwood P, Donovan H

10:35-10:40am
NCOG-13 The impact of neuro-oncology patients' neuropsychological function on family caregivers' emotional health
Cao X, Weimer J, Donovan H, Armstrong T, Ren D, Sherwood P

10:40-10:45am
PALL-01 Physician assisted suicide in high grade gliomas: A university-based practice perspective
Chamberlain M

10:45-10:50am
PALL-02 The impact and value of integrating palliative care into a neuro-oncology clinic
Manning M, Larach M, Boyles S, Stern A

10:50-11:00am Discussion

CONCURRENT SESSION 7C

Genetics/Epigenetics

Moderators: Daniel Cahill, C. David James

9:00-9:15am Invited Speaker: *Luis Parada*

9:15-9:30am
GENT-19 Insulator dysfunction as an oncogenic driver in glioma
Flavahan W, Drier Y, Tarjan D, Liau B, Gillespie S, Venteicher A, Stemmer-Rachamimov A, Suva M, Bernstein B

9:30-9:40am
GENT-06 In vivo expression of mutated IDH1 (R132H) gene in a mouse model of young adult glioblastoma has impact in median survival, DNA-repair pathways, autophagy and oligodendrocyte differentiation
Nunez FJ, Mendez FM, Koschmann C, Calinescu A, Saxena M, Kadiyala P, Savelieff M, Patel R, Manawar S, Venneti S, Dzaman M, Lowenstein PR, Castro MG

9:40-9:50am
GENT-07 Subgroup specific enhancers control distinct regulatory circuitries in ependymal tumors
Chavez L, Pajtler KW, Okonechnikov K, Gröbner S, Erkek S, Huang Z, Jones DTW, Witt H, Hovestadt V, Zapatka M, Korbel JO, Lichter PL, Pfister SM, Kool M

9:50-10:00am
GENT-49 Systematic identification of essential long non-coding RNA genes in glioblastoma
Liu S, Horlbeck M, Woo Cho S, Birk H, Malatesta M, He D, Villalta J, Cho M, Chen Y, Mandegar M, Olvera M, Conklin B, Chang H, Weissman J, Lim D

RAPID REPORTS

10:00-10:05am
GENT-13 Immunomethylomic assay of blood neutrophil lymphocyte ratio (NLR) in glioma survival
Wiencke J, Koestler D, Molinaro A, Wiemels J, Roy R, Hansen H, Rice T, Bracci P, McCoy L, Kelsey K, Wensch M, Christensen B

10:05-10:10am
GENT-18 Differential Brd4-bound stretch/super enhancers drive critical sex differences in GBM phenotype
Kfoury N, Qi Z, Berrett K, Kim A, Gertz J, Mitra R, Rubin J

10:10-10:15am
GENT-32 Comprehensive transcriptomic analysis of pediatric and adult human brain tumors for discovery of brain tumor-associated long non-coding RNAs
Niknafs Y, Parolia A, Shukla S, Venneti S, Chinnaiyan A

10:15-10:20am
GENT-33 Epigenetic alterations at intergenic regions associated with progression in a subset of IDH mutant gliomas
Sabedot TS, Malta T, Ceccarelli M, Dihn H, Berman B, Noushmehr H

10:20-10:25am
GENT-21 ATRX deficiency promotes invasion and alters the differentiation capacity of glioma cells of origin by dysregulating genome-wide chromatin accessibility and modulating transcriptional programs
Danussi C, Bose P, Parthasarathy P, Silberman P, Turcan S, Picketts D, Chan T, Huse

MAIN MEETING PROGRAM

Sunday, November 20, 2016

10:25-10:30am GENT-25	hTERT promoter hypermethylation is associated with unfavourable molecular subtypes and telomerase re-activation in pediatric ependymoma <u>Gojo J</u> , Löttsch D, Pajtler KW, Chavez L, Spiegel-Kreinecker S, Neumayer K, Korbel P, Araki A, Mohr M, Hovestadt V, Pfister SM, Czech T, Filipits M, Kool M, Peyrl A, Slavc I, Berger W, Haberler C
10:30-10:35am GENT-44	Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas <u>Venneti S</u> , Bayliss J, Mukherjee P, Lu C, Jain S, Martinez D, Margol A, Pekmezci M, Chung C, McEachin R, Cieslik M, Garcia B, Tamrazi B, Larocca G, Santi M, Lewis P, Melnik A, Allis C, Thompson C, Chinnaiyan A, Judkins A
10:35-10:40am MNGO-12	Clonal selection toward TERT promoter mutations in progressive recurrent meningiomas <u>Juratli T</u> , Kirsch M, Thiede C, Krex D, Krause M, Brastianos P, Cahill D, Schackert G
10:40-10:45am GENT-17	Sex-specific genome-wide analysis for loci associated with glioma risk <u>Ostrom Q</u> , Wensch M, Chen Y, Melin B, Wiencke J, Armstrong G, Rice T, McCoy L, Hansen H, Bondy M, Barnholtz-Sloan J
10:45-11:00am	Discussion
11:00-11:10am	BREAK

CONCURRENT SESSION 8A

Molecular Pathology II

Moderators: Craig Horbinski, Jason Huse

RAPID REPORTS

11:10-11:15am MPH-20	Preoperative serum microRNA profiling as a diagnostic tool in glioma <u>Morokoff A</u> , Bennett I, Paradiso L, Luwor R, Wong M, Koldej R, Li J, Ma C, Drummond K, Stylli S, Kaye A, Siegal T
11:15-11:20am DRES-16	A cerebrospinal fluid microRNA signature for assessment of glioblastoma tumor burden <u>Chen C</u> , Akers J, Ramakrishnan V, Mao Y, Hua W, Carter B
11:20-11:25am MPH-46	A pilot study identifying circulating cell-free tumor DNA alterations in patients with glioblastoma <u>Qlar A</u> , Ezhilarasan R, Mehrotra M, Manekia J, Singh R, Sulman E, Luthra R
11:25-11:30am MPH-56	Algorithm based liquid biopsy for the diagnosis of glioblastoma <u>Ray A</u> , Akolkar D

11:30-11:35am EPID-10	Association of known glioma germline risk SNPs within molecularly-defined groups <u>Eckel-Passow J</u> , Decker P, Kosel M, Kollmeyer T, Sarkar G, Caron A, Bracci P, Hansen H, Madsen N, McCoy L, Molinaro A, Rice T, Walsh K, Giannini C, Parney I, Wiemels J, Wiencke J, Melin B, Bondy M, Lachance D, Wensch M, Jenkins R
11:35-11:40am EPID-11	The contribution of the rs55705857 G allele to familial cancer risk using the Utah Population Database <u>Hummel S</u> , Kohlmann W, Kollmeyer T, Jenkins R, Sonnen J, Colman H, Abbott D, Cannon-Albright L, Cohen A
11:40-11:45am GENT-37	The genetics driving radiation induced meningiomas <u>Tonge P</u> , Agnihotri S, Jalali S, Danesh A, Bruce J, Pugh T, Aldape K, Zadeh G
11:45-11:50am MPH-18	Comprehensive mutational and cytogenetic analysis revealed genetic prognostic factors in grade II and III gliomas <u>Qlar A</u> , Ezhilarasan R, Mehrotra M, Manekia J, Singh R, Sulman E, Luthra R
11:50-12:00pm	Discussion

CONCURRENT SESSION 8B

Practical and Applied Neuro-Oncology II

Moderators: Martin Taphoorn, Tobias Walbert

RAPID REPORTS

11:10-11:15am QLIF-10	Family camp: a multi-disciplinary, holistic intervention for brain tumor patients and their families <u>Barani E</u> , Page M, Lovely MP, Marks A, Lamarre A, Patt J, Chang S, Clarke J
11:15-11:20am NCOG-11	Comparison of neurocognitive functioning in pediatric brain tumor survivors and children with neurodevelopmental ADHD <u>Sharkey C</u> , Gioia A, Willard V, Walsh K, Hardy K
11:20-11:25am QLIF-06	Sexual function in patients with primary brain tumors (PBTs) <u>Stone J</u> , DeAngelis L
11:25-11:30am NTOX-03	High rate of methotrexate-induced leukoencephalopathy in adult patients with CNS lymphoma carrying MTHFR single gene polymorphisms <u>Eisele S</u> , Gill C, Jones S, Pisapia M, Batchelor T, Plotkin S, Dietrich J
11:30-11:35am QLIF-17	The importance of the CERN Foundation adult ependymoma outcomes project <u>Acquaye AA</u> , Vera E, Gilbert MR, Armstrong TS

MAIN MEETING PROGRAM

Sunday, November 20, 2016

11:35-11:40am
QLIF-23
Functional outcome, symptom burden and survival vary by molecular subgroup in patients with anaplastic glioma
Kim M, Hervey-Jumper S, Tao Y, Schipper M, Orringer DA, Heth JA, Junck L, Mammoser A, Kim C, Lawrence T, Tsien C, Armstrong TS

11:40-11:45am
NCOG-15
A prospective study of hippocampal-sparing prophylactic cranial irradiation (PCI) in limited stage small cell lung cancer (SCLC)
Redmond K, Hales R, Zhuo XC, Kummerlowe M, Sair H, Duhon M, Kleinberg L, Rosner G, Vannorsdall T

11:45-11:50am
NCOG-16
Identifying cognitive impairment in patients with primary malignant brain tumors (PBMT)
Weimer J, Misko S, Drappatz J, Lieberman F, Donovan H, Sherwood P, Armstrong TS

11:50-12:00pm Discussion

CONCURRENT SESSION 8C

Cell Biology/Cell Signaling/Metabolomics

Moderators: Frank Furnari, Ingo Mellinghoff

11:10-11:20am
CBIO-05
Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells
ADULT TRANSLATIONAL RESEARCH AWARD
Lin H, Patel S, Affleck V, Wilson I, Turnbull D, Joshi A, Maxwell R, Stoll E

RAPID REPORTS

11:20-11:25am
CSIG-11
Role of Olig2 partner proteins in glioblastoma
LoCascio C, Kupp R, Singh S, Szeto E, Loo V, Rauf F, Derogatis A, Labaer J, Sanai N, Mehta S

11:25-11:30am
METB-06
Down regulation of phospholipid metabolism is a unique hallmark of mutant IDH1 glioma cells
Viswanath P, Izquierdo-Garcia JL, Phillips JJ, Pieper RO, Ronen S

11:30-11:35am
CBIO-19
Dissecting the multicellular ecosystem of human glioblastoma tumors using single cell mass cytometry
Leelatian N, Sinnaeve J, Mobley B, Weaver K, Thompson R, Chambless L, Ihrie R, Irish J

11:35-11:40am
CBIO-18
Haploinsufficiency of the regulator of the mutant TERT promoter reverses glioblastoma replicative immortality
Mancini A, Xavier-Magalhaes A, Woods W, Hayes J, Gapinske M, McKinney A, Bell R, Walsh K, Costa B, Song J, Perez-Pinera P, Costello J

11:40-11:45am
CBIO-20
Metabolic vulnerability revealed in slow-cycling glioma stem cells
Hoang-Minh L, Schmoll M, Amin K, Dajac K, Vuong A, Huang J, Yang C, Garrett T, Sarkisian M, Reynolds B, Deleyrolle L

11:45-11:50am
CSIG-27
An RNAi kinome screen identifies the YES1 kinase as a potential target for glioblastoma
Goel-Bhattacharya S, Sengupta S, Cochran B

11:50-12:00pm Discussion

12:00-12:30pm
Highlights of SNO 2016
Manish Aghi, Tracy Batchelor

12:30pm
ADJOURN



Society for Neuro-Oncology

PO Box 273296 Houston, TX 77277-3296

Tel: 713-526-6900 E-Fax: 801-421-0269

www.soc-neuro-onc.org

THE UNIVERSITY OF TEXAS

MDAnderson
~~Cancer~~ Center

Making Cancer History®